Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases

Abstract

Iron (Fe) and copper (Cu) are vital micronutrients that regulate many critical physiological processes in the human body, with their homeostasis in the central nervous system (CNS) being essential for proper neuronal function. Disruptions in their metabolism and regulatory pathways have been associated with the pathogenesis of various forms of neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD). Despite growing research on metal homeostasis, the intricate molecular mechanisms that link iron and copper metabolism to the initiation and progression of NDDs remain insufficiently elucidated. In this review, we provide a systematic overview of the metabolic processes of iron and copper in the body and CNS, highlighting their interactions with many metal-binding proteins, including transporters, storage proteins, and important intrinsically disordered proteins (e.g., amyloid β-protein, tau, and alpha-synuclein) involved in NDDs. We further dissect the downstream effects of metal ion dyshomeostasis on cellular redox balance, neuroinflammation, autophagy, organelle interaction network, and cell death. Additionally, we discuss current therapeutic strategies aimed at targeting iron and copper dyshomeostasis, as well as the emerging role of artificial intelligence in this field of research. By integrating metal metabolism, metal–protein interactions, the effect of metal dyshomeostasis on downstream biological processes, and potential intervention strategies, this review serves as a comprehensive reference for understanding the pathogenesis of NDDs and offers new perspectives for developing effective therapeutics. Overall, this review underscores the significance of reinstating metal balance for the treatment of neurodegeneration.

Keywords

intrinsically disordered proteins / iron and copper homeostasis / metal-binding proteins / neurodegenerative diseases / therapeutic agents

References

[1] D. M. Wilson, M. R. Cookson, L. Van Den Bosch, H. Zetterberg, D. M. Holtzman, and I. Dewachter, “Hallmarks of Neurodegenerative Diseases,” Cell 186, no. 4 (2023): 693–714.

[2] Y. Hou, X. Dan, M. Babbar, et al., “Ageing as a Risk Factor for Neurodegenerative Disease,” Nature Reviews Neurology 15, no. 10 (2019): 565–581.

[3] M. U. Rehman, N. Sehar, N. J. Dar, et al., “Mitochondrial Dysfunctions, Oxidative Stress and Neuroinflammation as Therapeutic Targets for Neurodegenerative Diseases: An Update on Current Advances and Impediments,” Neuroscience and Biobehavioral Reviews 144 (2023): 104961.

[4] H. Wang, F. Yang, S. Zhang, R. Xin, and Y. Sun, “Genetic and Environmental Factors in Alzheimer's and Parkinson's Diseases and Promising Therapeutic Intervention via Fecal Microbiota Transplantation,” NPJ Parkinson's Disease 7, no. 1 (2021): 70.

[5] P. Lei, T. Walker, and S. Ayton, “Neuroferroptosis in Health and Diseases,” Nature Reviews Neuroscience 26, no. 8 (2025): 497–511.

[6] L. Chen, Q. Shen, Y. Liu, et al., “Homeostasis and Metabolism of Iron and Other Metal Ions in Neurodegenerative Diseases,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 31.

[7] L. Chen, J. Min, and F. Wang, “Copper Homeostasis and Cuproptosis in Health and Disease,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 378.

[8] Y. Yang, J. Wu, L. Wang, G. Ji, and Y. Dang, “Copper Homeostasis and Cuproptosis in Health and Disease,” MedComm 5 (2024): e724.

[9] R. Trivedi and H. A. Nagarajaram, “Intrinsically Disordered Proteins: An Overview,” International Journal of Molecular Sciences 23, no. 22 (2022): 14050.

[10] G. J. Anderson and D. M. Frazer, “Current Understanding of Iron Homeostasis,” American Journal of Clinical Nutrition 106, no. suppl 6 (2017): 1559s–1566s.

[11] I. M. Zijp, O. Korver, and L. B. Tijburg, “Effect of Tea and Other Dietary Factors on Iron Absorption,” Critical Reviews in Food Science and Nutrition 40, no. 5 (2000): 371–398.

[12] A. T. McKie, D. Barrow, G. O. Latunde-Dada, et al., “An Iron-Regulated Ferric Reductase Associated With the Absorption of Dietary Iron,” Science 291, no. 5509 (2001): 1755–1759.

[13] M. D. Garrick, K. G. Dolan, C. Horbinski, et al., “DMT1: A Mammalian Transporter for Multiple Metals,” Biometals 16, no. 1 (2003): 41–54.

[14] A. Nandal, J. C. Ruiz, P. Subramanian, et al., “Activation of the HIF Prolyl Hydroxylase by the Iron Chaperones PCBP1 and PCBP2,” Cell Metabolism 14, no. 5 (2011): 647–657.

[15] S. Leidgens, K. Z. Bullough, H. Shi, et al., “Each Member of the Poly-r(C)-Binding Protein 1 (PCBP) Family Exhibits Iron Chaperone Activity Toward Ferritin,” Journal of Biological Chemistry 288, no. 24 (2013): 17791–17802.

[16] A. Donovan, A. Brownlie, Y. Zhou, et al., “Positional Cloning of Zebrafish Ferroportin1 Identifies a Conserved Vertebrate Iron Exporter,” Nature 403, no. 6771 (2000): 776–781.

[17] L. Qiu, D. M. Frazer, M. Hu, et al., “Mechanism and Regulation of Iron Absorption Throughout the Life Cycle,” Journal of Advanced Research 77 (2025): 107–118.

[18] S. Gulec, G. J. Anderson, and J. F. Collins, “Mechanistic and Regulatory Aspects of Intestinal Iron Absorption,” American Journal of Physiology Gastrointestinal and Liver Physiology 307, no. 4 (2014): G397–G409.

[19] L. L. Chen, Y. J. Huang, J. T. Cui, N. Song, and J. Xie, “Iron Dysregulation in Parkinson's Disease: Focused on the Autophagy-Lysosome Pathway,” ACS Chemical Neuroscience 10, no. 2 (2019): 863–871.

[20] Z. Xiao, X. Wang, X. Pan, J. Xie, and H. Xu, “Mitochondrial Iron Dyshomeostasis and Its Potential as a Therapeutic Target for Parkinson's Disease,” Experimental Neurology 372 (2024): 114614.

[21] A. Cabrera, E. Alonzo, E. Sauble, et al., “Copper Binding Components of Blood Plasma and Organs, and Their Responses to Influx of Large Doses of (65)Cu, in the Mouse,” Biometals 21, no. 5 (2008): 525–543.

[22] V. K. Wandt, N. Winkelbeiner, J. Bornhorst, et al., “A Matter of Concern—Trace Element Dyshomeostasis and Genomic Stability in Neurons,” Redox Biology 41 (2021): 101877.

[23] B. Lönnerdal, “Intestinal Regulation of Copper Homeostasis: A Developmental Perspective,” American Journal of Clinical Nutrition 88, no. 3 (2008): 846s–850s.

[24] S. Lutsenko, “Dynamic and Cell-Specific Transport Networks for Intracellular Copper Ions,” Journal of Cell Science 134, no. 21 (2021): cs240523.

[25] S. Hernandez, Y. Tsuchiya, J. P. García-Ruiz, et al., “ATP7B Copper-Regulated Traffic and Association With the Tight Junctions: Copper Excretion Into the Bile,” Gastroenterology 134, no. 4 (2008): 1215–1223.

[26] R. S. Ohgami, D. R. Campagna, A. McDonald, and M. D. Fleming, “The Steap Proteins Are Metalloreductases,” Blood 108, no. 4 (2006): 1388–1394.

[27] X. Zhu, A. Boulet, K. M. Buckley, et al., “Mitochondrial Copper and Phosphate Transporter Specificity Was Defined Early in the Evolution of Eukaryotes,” Elife 10 (2021): e64690.

[28] J. Xie, Y. Yang, Y. Gao, and J. He, “Cuproptosis: Mechanisms and Links With Cancers,” Molecular Cancer 22, no. 1 (2023): 46.

[29] M. J. van Rensburg, M. van Rooy, M. J. Bester, J. C. Serem, C. Venter, and H. M. Oberholzer, “Oxidative and Haemostatic Effects of Copper, Manganese and Mercury, Alone and in Combination at Physiologically Relevant Levels: An Ex Vivo Study,” Human & Experimental Toxicology 38, no. 4 (2019): 419–433.

[30] B. E. Kim, T. Nevitt, and D. J. Thiele, “Mechanisms for Copper Acquisition, Distribution and Regulation,” Nature Chemical Biology 4, no. 3 (2008): 176–185.

[31] R. L. Casareno, D. Waggoner, and J. D. Gitlin, “The Copper Chaperone CCS Directly Interacts With Copper/Zinc Superoxide Dismutase,” Journal of Biological Chemistry 273, no. 37 (1998): 23625–23628.

[32] F. Yang, L. Jia, H. C. Zhou, et al., “Deep Learning Enables the Discovery of a Novel Cuproptosis-inducing Molecule for the Inhibition of Hepatocellular Carcinoma,” Acta Pharmacologica Sinica 45, no. 2 (2024): 391–404.

[33] Y. Furukawa, A. S. Torres, and T. V. O'Halloran, “Oxygen-Induced Maturation of SOD1: A Key Role for Disulfide Formation by the Copper Chaperone CCS,” EMBO Journal 23, no. 14 (2004): 2872–2881.

[34] X. Dong, Z. Zhang, J. Zhao, et al., “The Rational Design of Specific SOD1 Inhibitors via Copper Coordination and Their Application in ROS Signaling Research,” Chemical Science 7, no. 9 (2016): 6251–6262.

[35] S. C. Dodani, S. C. Leary, P. A. Cobine, D. R. Winge, and C. J. Chang, “A Targetable Fluorescent Sensor Reveals That Copper-Deficient SCO1 and SCO2 Patient Cells Prioritize Mitochondrial Copper Homeostasis,” Journal of the American Chemical Society 133, no. 22 (2011): 8606–8616.

[36] F. A. Punter, D. L. Adams, and D. M. Glerum, “Characterization and Localization of Human COX17, a Gene Involved in Mitochondrial Copper Transport,” Human Genetics 107, no. 1 (2000): 69–74.

[37] L. Banci, I. Bertini, S. Ciofi-Baffoni, T. Hadjiloi, M. Martinelli, and P. Palumaa, “Mitochondrial Copper(I) Transfer From Cox17 to Sco1 Is Coupled to Electron Transfer,” PNAS 105, no. 19 (2008): 6803–6808.

[38] D. Pacheu-Grau, M. Wasilewski, S. Oeljeklaus, et al., “COA6 Facilitates Cytochrome c Oxidase Biogenesis as Thiol-Reductase for Copper Metallochaperones in Mitochondria,” Journal of Molecular Biology 432, no. 7 (2020): 2067–2079.

[39] S. Soma, M. N. Morgada, M. T. Naik, et al., “COA6 Is Structurally Tuned to Function as a Thiol-Disulfide Oxidoreductase in Copper Delivery to Mitochondrial Cytochrome c Oxidase,” Cell Reports 29, no. 12 (2019): 4114–4126.e4115.

[40] A. Ghosh, P. P. Trivedi, S. A. Timbalia, et al., “Copper Supplementation Restores Cytochrome c Oxidase Assembly Defect in a Mitochondrial Disease Model of COA6 Deficiency,” Human Molecular Genetics 23, no. 13 (2014): 3596–3606.

[41] Y. C. Horng, S. C. Leary, P. A. Cobine, et al., “Human Sco1 and Sco2 Function as Copper-Binding Proteins,” Journal of Biological Chemistry 280, no. 40 (2005): 34113–34122.

[42] S. C. Leary, P. A. Cobine, B. A. Kaufman, et al., “The Human Cytochrome c Oxidase Assembly Factors SCO1 and SCO2 Have Regulatory Roles in the Maintenance of Cellular Copper Homeostasis,” Cell Metabolism 5, no. 1 (2007): 9–20.

[43] C. Doguer, J. H. Ha, and J. F. Collins, “Intersection of Iron and Copper Metabolism in the Mammalian Intestine and Liver,” Comprehensive Physiology 8, no. 4 (2018): 1433–1461.

[44] Z. D. Zhou and E. K. Tan, “Iron Regulatory Protein (IRP)-Iron Responsive Element (IRE) Signaling Pathway in Human Neurodegenerative Diseases,” Molecular Neurodegeneration 12, no. 1 (2017): 75.

[45] T. Skjørringe, L. B. Møller, and T. Moos, “Impairment of Interrelated Iron- and Copper Homeostatic Mechanisms in Brain Contributes to the Pathogenesis of Neurodegenerative Disorders,” Frontiers in Pharmacology 3 (2012): 169.

[46] S. Oshiro, K. Nozawa, M. Hori, et al., “Modulation of Iron Regulatory Protein-1 by Various Metals,” Biochemical and Biophysical Research Communications 290, no. 1 (2002): 213–218.

[47] J. Tennant, M. Stansfield, S. Yamaji, S. K. Srai, and P. Sharp, “Effects of Copper on the Expression of Metal Transporters in Human Intestinal Caco-2 Cells,” FEBS Letters 527, no. 1–3 (2002): 239–244.

[48] S. Balesaria, B. Ramesh, H. McArdle, H. K. Bayele, and S. K. Srai, “Divalent Metal-Dependent Regulation of Hepcidin Expression by MTF-1,” FEBS Letters 584, no. 4 (2010): 719–725.

[49] H. Jiayi, T. Ziyuan, X. Tianhua, et al., “Copper Homeostasis in Chronic Kidney Disease and Its Crosstalk With Ferroptosis,” Pharmacological Research 202 (2024): 107139.

[50] A. D. Monnot, G. Zheng, and W. Zheng, “Mechanism of Copper Transport at the Blood-Cerebrospinal Fluid Barrier: Influence of Iron Deficiency in an In Vitro Model,” Experimental Biology and Medicine (Maywood) 237, no. 3 (2012): 327–333.

[51] J. F. Collins, C. A. Franck, K. V. Kowdley, and F. K. Ghishan, “Identification of Differentially Expressed Genes in Response to Dietary Iron Deprivation in Rat Duodenum,” American Journal of Physiology Gastrointestinal and Liver Physiology 288, no. 5 (2005): G964–G971.

[52] A. D. Monnot, M. Behl, S. Ho, and W. Zheng, “Regulation of Brain Copper Homeostasis by the Brain Barrier Systems: Effects of Fe-Overload and Fe-Deficiency,” Toxicology and Applied Pharmacology 256, no. 3 (2011): 249–257.

[53] L. Xie and J. F. Collins, “Transcriptional Regulation of the Menkes Copper ATPase (Atp7a) Gene by Hypoxia-Inducible Factor (HIF2{Alpha}) in Intestinal Epithelial Cells,” American Journal of Physiology Cell Physiology 300, no. 6 (2011): C1298–C1305.

[54] T. Moos, T. Rosengren Nielsen, T. Skjørringe, and E. H. Morgan, “Iron Trafficking Inside the Brain,” Journal of Neurochemistry 103, no. 5 (2007): 1730–1740.

[55] J. H. Ha, C. Doguer, X. Wang, S. R. Flores, and J. F. Collins, “High-Iron Consumption Impairs Growth and Causes Copper-Deficiency Anemia in Weanling Sprague-Dawley Rats,” PLoS ONE 11, no. 8 (2016): e0161033.

[56] M. Bulk, L. van der Weerd, W. Breimer, et al., “Quantitative Comparison of Different Iron Forms in the Temporal Cortex of Alzheimer Patients and Control Subjects,” Scientific Reports 8, no. 1 (2018): 6898.

[57] P. Ramos, A. Santos, N. R. Pinto, R. Mendes, T. Magalhães, and A. Almeida, “Iron Levels in the Human Brain: A Post-Mortem Study of Anatomical Region Differences and Age-Related Changes,” Journal of Trace Elements in Medicine and Biology 28, no. 1 (2014): 13–17.

[58] M. Cerasuolo, I. Di Meo, M. C. Auriemma, et al., “Iron and Ferroptosis More Than a Suspect: Beyond the Most Common Mechanisms of Neurodegeneration for New Therapeutic Approaches to Cognitive Decline and Dementia,” International Journal of Molecular Sciences 24, no. 11 (2023): 9637.

[59] T. W. Bastian, W. C. von Hohenberg, M. K. Georgieff, and L. M. Lanier, “Chronic Energy Depletion due to Iron Deficiency Impairs Dendritic Mitochondrial Motility During Hippocampal Neuron Development,” Journal of Neuroscience 39, no. 5 (2019): 802–813.

[60] X. Wang, D. S. Miller, and W. Zheng, “Intracellular Localization and Subsequent Redistribution of Metal Transporters in a Rat Choroid Plexus Model Following Exposure to Manganese or Iron,” Toxicology and Applied Pharmacology 230, no. 2 (2008): 167–174.

[61] E. Isasi, M. Figares, V. Abudara, and S. Olivera-Bravo, “Gestational and Lactational Iron Deficiency Anemia Impairs Myelination and the Neurovascular Unit in Infant Rats,” Molecular Neurobiology 59, no. 6 (2022): 3738–3754.

[62] Q. Gao, Y. Zhou, Y. Chen, et al., “Role of Iron in Brain Development, Aging, and Neurodegenerative Diseases,” Annals of Medicine 57, no. 1 (2025): 2472871.

[63] B. Larsen, J. Bourque, T. M. Moore, et al., “Longitudinal Development of Brain Iron Is Linked to Cognition in Youth,” Journal of Neuroscience 40, no. 9 (2020): 1810–1818.

[64] Y. Ke and Z. M. Qian, “Brain Iron Metabolism: Neurobiology and Neurochemistry,” Progress in Neurobiology 83, no. 3 (2007): 149–173.

[65] D. F. Leitner and J. R. Connor, “Functional Roles of Transferrin in the Brain,” Biochimica et Biophysica Acta 1820, no. 3 (2012): 393–402.

[66] X. Wang, G. J. Li, and W. Zheng, “Efflux of Iron From the Cerebrospinal Fluid to the Blood at the Blood-CSF Barrier: Effect of Manganese Exposure,” Experimental Biology and Medicine (Maywood) 233, no. 12 (2008): 1561–1571.

[67] R. Dringen, G. M. Bishop, M. Koeppe, T. N. Dang, and S. R. Robinson, “The Pivotal Role of Astrocytes in the Metabolism of Iron in the Brain,” Neurochemical Research 32, no. 11 (2007): 1884–1890.

[68] T. A. Rouault, “Iron Metabolism in the CNS: Implications for Neurodegenerative Diseases,” Nature Reviews Neuroscience 14, no. 8 (2013): 551–564.

[69] R. C. McCarthy and D. J. Kosman, “Iron Transport Across the Blood-Brain Barrier: Development, Neurovascular Regulation and Cerebral Amyloid Angiopathy,” Cellular and Molecular Life Sciences 72, no. 4 (2015): 709–727.

[70] Z. D. Li, H. Li, S. Kang, et al., “The Divergent Effects of Astrocyte Ceruloplasmin on Learning and Memory Function in Young and Old Mice,” Cell Death & Disease 13, no. 11 (2022): 1006.

[71] J. Li, B. Jia, Y. Cheng, Y. Song, Q. Li, and C. Luo, “Targeting Molecular Mediators of Ferroptosis and Oxidative Stress for Neurological Disorders,” Oxidative Medicine and Cellular Longevity 2022 (2022): 3999083.

[72] L. J. Routhe, I. K. Andersen, L. V. Hauerslev, I. I. Issa, T. Moos, and M. S. Thomsen, “Astrocytic Expression of ZIP14 (SLC39A14) Is Part of the Inflammatory Reaction in Chronic Neurodegeneration With Iron Overload,” Glia 68, no. 9 (2020): 1810–1823.

[73] L. Ma, M. Gholam Azad, M. Dharmasivam, et al., “Parkinson's Disease: Alterations in Iron and Redox Biology as a Key to Unlock Therapeutic Strategies,” Redox Biology 41 (2021): 101896.

[74] C. Ji, B. L. Steimle, D. K. Bailey, and D. J. Kosman, “The Ferroxidase Hephaestin but Not Amyloid Precursor Protein Is Required for Ferroportin-Supported Iron Efflux in Primary Hippocampal Neurons,” Cellular and Molecular Neurobiology 38, no. 4 (2018): 941–954.

[75] V. T. Cheli, D. A. Santiago González, R. Wan, et al., “Transferrin Receptor Is Necessary for Proper Oligodendrocyte Iron Homeostasis and Development,” Journal of Neuroscience 43, no. 20 (2023): 3614–3629.

[76] B. Chiou, E. Lucassen, M. Sather, A. Kallianpur, and J. Connor, “Semaphorin4A and H-Ferritin Utilize Tim-1 on Human Oligodendrocytes: A Novel Neuro-Immune Axis,” Glia 66, no. 7 (2018): 1317–1330.

[77] J. G. Zarruk, J. L. Berard, R. Passos dos Santos, et al., “Expression of Iron Homeostasis Proteins in the Spinal Cord in Experimental Autoimmune Encephalomyelitis and Their Implications for Iron Accumulation,” Neurobiology of Disease 81 (2015): 93–107.

[78] A. G. Barbeito, T. Levade, M. B. Delisle, B. Ghetti, and R. Vidal, “Abnormal Iron Metabolism in Fibroblasts From a Patient With the Neurodegenerative Disease Hereditary Ferritinopathy,” Molecular Neurodegeneration 5 (2010): 50.

[79] I. F. Scheiber, J. F. Mercer, and R. Dringen, “Metabolism and Functions of Copper in Brain,” Progress in Neurobiology 116 (2014): 33–57.

[80] P. Faller and C. Hureau, “A Bioinorganic View of Alzheimer's Disease: When Misplaced Metal Ions (Re)Direct the Electrons to the Wrong Target,” Chemistry 18, no. 50 (2012): 15910–15920.

[81] E. J. Ge, A. I. Bush, A. Casini, et al., “Connecting Copper and Cancer: From Transition Metal Signalling to Metalloplasia,” Nature Reviews Cancer 22, no. 2 (2022): 102–113.

[82] W. Zheng and A. D. Monnot, “Regulation of Brain Iron and Copper Homeostasis by Brain Barrier Systems: Implication in Neurodegenerative Diseases,” Pharmacology & Therapeutics 133, no. 2 (2012): 177–188.

[83] J. Lee, M. J. Petris, and D. J. Thiele, “Characterization of Mouse Embryonic Cells Deficient in the Ctr1 High Affinity Copper Transporter. Identification of a Ctr1-Independent Copper Transport System,” Journal of Biological Chemistry 277, no. 43 (2002): 40253–40259.

[84] J. Telianidis, Y. H. Hung, S. Materia, and S. L. Fontaine, “Role of the P-Type ATPases, ATP7A and ATP7B in Brain Copper Homeostasis,” Frontiers in Aging Neuroscience 5 (2013): 44.

[85] M. Nedergaard, B. Ransom, and S. A. Goldman, “New Roles for Astrocytes: Redefining the Functional Architecture of the Brain,” Trends in Neuroscience 26, no. 10 (2003): 523–530.

[86] H. H. Hoepken, T. Korten, S. R. Robinson, and R. Dringen, “Iron Accumulation, Iron-Mediated Toxicity and Altered Levels of Ferritin and Transferrin Receptor in Cultured Astrocytes During Incubation With Ferric Ammonium Citrate,” Journal of Neurochemistry 88, no. 5 (2004): 1194–1202.

[87] B. Sullivan, G. Robison, J. Osborn, et al., “On the Nature of the Cu-Rich Aggregates in Brain Astrocytes,” Redox Biology 11 (2017): 231–239.

[88] T. Adachi, M. Satoh, R. Pramanik, S. Kuroda, M. Ishido, and M. Kunimoto, “Region-Dependent Differences and Alterations of Protective Thiol Compound Levels in Cultured Astrocytes and Brain Tissues,” Biological & Pharmaceutical Bulletin 29, no. 7 (2006): 1466–1469.

[89] I. F. Scheiber and R. Dringen, “Copper-Treatment Increases the Cellular GSH Content and Accelerates GSH Export From Cultured Rat Astrocytes,” Neuroscience Letters 498, no. 1 (2011): 42–46.

[90] I. F. Scheiber, M. M. Schmidt, and R. Dringen, “Copper Export From Cultured Astrocytes,” Neurochemistry International 60, no. 3 (2012): 292–300.

[91] S. A. Pope, R. Milton, and S. J. Heales, “Astrocytes Protect Against Copper-Catalysed Loss of Extracellular Glutathione,” Neurochemical Research 33, no. 7 (2008): 1410–1418.

[92] G. A. Dienel, “Brain Lactate Metabolism: The Discoveries and the Controversies,” Journal of Cerebral Blood Flow and Metabolism 32, no. 7 (2012): 1107–1138.

[93] M. Sohrabi, M. R. Bozorgmehr, and M. Momen-Heravi, “Investigating the Combined Effect of Copper, Zinc, and Iron Ions on Truncated and Full-Length Aβ Peptides: Insights From Molecular Dynamics Simulation,” Journal of Biomolecular Structure & Dynamics 43, no. 8 (2025): 4165–4173.

[94] V. N. Uversky, J. Li, and A. L. Fink, “Metal-Triggered Structural Transformations, Aggregation, and Fibrillation of Human Alpha-Synuclein. A Possible Molecular NK Between Parkinson's Disease and Heavy Metal Exposure,” Journal of Biological Chemistry 276, no. 47 (2001): 44284–44296.

[95] A. K. Tripathi, S. Haldar, J. Qian, et al., “Prion Protein Functions as a Ferrireductase Partner for ZIP14 and DMT1,” Free Radical Biology and Medicine 84 (2015): 322–330.

[96] D. W. Donley, M. Realing, J. P. Gigley, and J. H. Fox, “Iron Activates Microglia and Directly Stimulates Indoleamine-2,3-Dioxygenase Activity in the N171-82Q Mouse Model of Huntington's Disease,” PLoS ONE 16, no. 5 (2021): e0250606.

[97] S. Agrawal, J. Fox, B. Thyagarajan, and J. H. Fox, “Brain Mitochondrial Iron Accumulates in Huntington's Disease, Mediates Mitochondrial Dysfunction, and Can be Removed Pharmacologically,” Free Radical Biology and Medicine 120 (2018): 317–329.

[98] J. K. Lee, J. H. Shin, B. J. Gwag, and E. J. Choi, “Iron Accumulation Promotes TACE-Mediated TNF-α Secretion and Neurodegeneration in a Mouse Model of ALS,” Neurobiology of Disease 80 (2015): 63–69.

[99] T. Wang, D. Tomas, N. D. Perera, et al., “Ferroptosis Mediates Selective Motor Neuron Death in Amyotrophic Lateral Sclerosis,” Cell Death and Differentiation 29, no. 6 (2022): 1187–1198.

[100] D. Wang, W. Liang, D. Huo, et al., “SPY1 Inhibits Neuronal Ferroptosis in Amyotrophic Lateral Sclerosis by Reducing Lipid Peroxidation Through Regulation of GCH1 and TFR1,” Cell Death and Differentiation 30, no. 2 (2023): 369–382.

[101] J. Jeon, F. Bu, G. Sun, et al., “Contribution of TRPC Channels in Neuronal Excitotoxicity Associated With Neurodegenerative Disease and Ischemic Stroke,” Frontiers in Cell and Developmental Biology 8 (2020): 618663.

[102] C. Guo, L. Sun, X. Chen, and D. Zhang, “Oxidative Stress, Mitochondrial Damage and Neurodegenerative Diseases,” Neural Regeneration Research 8, no. 21 (2013): 2003–2014.

[103] M. Bialasek, M. Kubiak, M. Gorczak, et al., “Exploiting Iron-Binding Proteins for Drug Delivery,” Journal of Physiology and Pharmacology 70, no. 5 (2019): 675–685.

[104] H. Li and Z. M. Qian, “Transferrin/Transferrin Receptor-Mediated Drug Delivery,” Medicinal Research Reviews 22, no. 3 (2002): 225–250.

[105] L. Bai, T. Xie, Q. Hu, C. Deng, R. Zheng, and W. Chen, “Genome-Wide Comparison of Ferritin family From Archaea, Bacteria, Eukarya, and Viruses: Its Distribution, Characteristic Motif, and Phylogenetic Relationship,” Die Naturwissenschaften 102, no. 9–10 (2015): 64.

[106] V. de Turris, M. Cardoso Trabuco, G. Peruzzi, et al., “Humanized Archaeal Ferritin as a Tool for Cell Targeted Delivery,” Nanoscale 9, no. 2 (2017): 647–655.

[107] M. Kim, Y. Rho, K. S. Jin, et al., “pH-Dependent Structures of Ferritin and Apoferritin in Solution: Disassembly and Reassembly,” Biomacromolecules 12, no. 5 (2011): 1629–1640.

[108] C. B. Billesbølle, C. M. Azumaya, R. C. Kretsch, et al., “Structure of Hepcidin-Bound Ferroportin Reveals Iron Homeostatic Mechanisms,” Nature 586, no. 7831 (2020): 807–811.

[109] P. Agarwal, S. Ayton, S. Agrawal, et al., “Brain Copper May Protect From Cognitive Decline and Alzheimer's Disease Pathology: A Community-Based Study,” Molecular Psychiatry 27, no. 10 (2022): 4307–4313.

[110] S. Bucossi, M. Ventriglia, V. Panetta, et al., “Copper in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies,” Journal of Alzheimer's Disease 24, no. 1 (2011): 175–185.

[111] S. Genoud, A. M. Senior, D. J. Hare, and K. L. Double, “Meta-Analysis of Copper and Iron in Parkinson's Disease Brain and Biofluids,” Movement Disorders 35, no. 4 (2020): 662–671.

[112] S. Montes, S. Rivera-Mancia, A. Diaz-Ruiz, L. Tristan-Lopez, and C. Rios, “Copper and Copper Proteins in Parkinson's Disease,” Oxidative Medicine and Cellular Longevity 2014 (2014): 147251.

[113] M. K. Gangania, J. Batra, S. Kushwaha, and R. Agarwal, “Role of Iron and Copper in the Pathogenesis of Parkinson's Disease,” Indian Journal of Clinical Biochemistry 32, no. 3 (2017): 353–356.

[114] B. Tarnacka, A. Jopowicz, and M. Maślińska, “Copper, Iron, and Manganese Toxicity in Neuropsychiatric Conditions,” International Journal of Molecular Sciences 22, no. 15 (2021): 7820.

[115] A. C. Pfalzer, Y. Yan, H. Kang, et al., “Alterations in Metal Homeostasis Occur Prior to Canonical Markers in Huntington Disease,” Scientific Reports 12, no. 1 (2022): 10373.

[116] G. Gromadzka, M. Grycan, and A. M. Przybyłkowski, “Monitoring of Copper in Wilson Disease,” Diagnostics (Basel) 13, no. 11 (2023): 1830.

[117] M. Scholefield, R. D. Unwin, and G. J. S. Cooper, “Shared Perturbations in the Metallome and Metabolome of Alzheimer's, Parkinson's, Huntington's, and Dementia With Lewy Bodies: A Systematic Review,” Ageing Research Reviews 63 (2020): 101152.

[118] N. Horn and P. Wittung-Stafshede, “ATP7A-Regulated Enzyme Metalation and Trafficking in the Menkes Disease Puzzle,” Biomedicines 9, no. 4 (2021): 391.

[119] R. Giampietro, F. Spinelli, M. Contino, and N. A. Colabufo, “The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders,” Molecular Pharmaceutics 15, no. 3 (2018): 808–820.

[120] L. Sauzéat, E. Bernard, A. Perret-Liaudet, et al., “Isotopic Evidence for Disrupted Copper Metabolism in Amyotrophic Lateral Sclerosis,” Iscience 6 (2018): 264–271.

[121] K. Burk and R. J. Pasterkamp, “Disrupted Neuronal Trafficking in Amyotrophic Lateral Sclerosis,” Acta Neuropathologica 137, no. 6 (2019): 859–877.

[122] T. G. Enge, H. Ecroyd, D. F. Jolley, J. J. Yerbury, B. Kalmar, and A. Dosseto, “Assessment of Metal Concentrations in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis and Its Potential Role in Muscular Denervation, With Particular Focus on Muscle Tissue,” Molecular and Cellular Neuroscience 88 (2018): 319–329.

[123] E. Colombo, D. Triolo, C. Bassani, et al., “Dysregulated Copper Transport in Multiple Sclerosis May Cause Demyelination via Astrocytes,” PNAS 118, no. 27 (2021): e2025804118.

[124] L. De Riccardis, A. Buccolieri, M. Muci, et al., “Copper and Ceruloplasmin Dyshomeostasis in Serum and Cerebrospinal Fluid of Multiple Sclerosis Subjects,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864, no. 5 pt A (2018): 1828–1838.

[125] B. Zhou and J. Gitschier, “hCTR1: A human Gene for Copper Uptake Identified by Complementation in Yeast,” PNAS 94, no. 14 (1997): 7481–7486.

[126] S. Lutsenko, A. Bhattacharjee, and A. L. Hubbard, “Copper Handling Machinery of the Brain,” Metallomics 2, no. 9 (2010): 596–608.

[127] K. M. Davies, D. J. Hare, V. Cottam, et al., “Localization of Copper and Copper Transporters in the Human Brain,” Metallomics 5, no. 1 (2013): 43–51.

[128] C. A. Larson, P. L. Adams, D. D. Jandial, B. G. Blair, R. Safaei, and S. B. Howell, “The Role of the N-Terminus of Mammalian Copper Transporter 1 in the Cellular Accumulation of Cisplatin,” Biochemical Pharmacology 80, no. 4 (2010): 448–454.

[129] S. Puig, J. Lee, M. Lau, and D. J. Thiele, “Biochemical and Genetic Analyses of Yeast and Human High Affinity Copper Transporters Suggest a Conserved Mechanism for Copper Uptake,” Journal of Biological Chemistry 277, no. 29 (2002): 26021–26030.

[130] P. V. van den Berghe and L. W. Klomp, “Posttranslational Regulation of Copper Transporters,” Journal of Biological Inorganic Chemistry 15, no. 1 (2010): 37–46.

[131] Y. Guo, K. Smith, J. Lee, D. J. Thiele, and M. J. Petris, “Identification of Methionine-Rich Clusters That Regulate Copper-Stimulated Endocytosis of the Human Ctr1 Copper Transporter,” Journal of Biological Chemistry 279, no. 17 (2004): 17428–17433.

[132] P. Abada and S. B. Howell, “Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters,” Metal Based Drugs 2010 (2010): 317581.

[133] Y. Nose, L. K. Wood, B. E. Kim, et al., “Ctr1 is an Apical Copper Transporter in Mammalian Intestinal Epithelial Cells In Vivo That is Controlled at the Level of Protein Stability,” Journal of Biological Chemistry 285, no. 42 (2010): 32385–32392.

[134] E. B. Maryon, S. A. Molloy, and J. H. Kaplan, “O-Linked Glycosylation at Threonine 27 Protects the Copper Transporter hCTR1 From Proteolytic Cleavage in Mammalian Cells,” Journal of Biological Chemistry 282, no. 28 (2007): 20376–20387.

[135] X. Du, H. Li, X. Wang, Q. Liu, J. Ni, and H. Sun, “Kinetics and Thermodynamics of Metal Binding to the N-Terminus of a Human Copper Transporter, hCTR1,” Chemical Communications (Cambridge) 49, no. 80 (2013): 9134–9136.

[136] C. J. De Feo, S. G. Aller, G. S. Siluvai, N. J. Blackburn, and V. M. Unger, “Three-Dimensional Structure of the Human Copper Transporter hCTR1,” PNAS 106, no. 11 (2009): 4237–4242.

[137] J. Calvo, H. Jung, and G. Meloni, “Copper Metallothioneins,” IUBMB Life 69, no. 4 (2017): 236–245.

[138] R. K. Stankovic, R. S. Chung, and M. Penkowa, “Metallothioneins I and II: Neuroprotective Significance During CNS Pathology,” International Journal of Biochemistry & Cell Biology 39, no. 3 (2007): 484–489.

[139] Y. Uchida, K. Takio, K. Titani, Y. Ihara, and M. Tomonaga, “The Growth Inhibitory Factor That Is Deficient in the Alzheimer's Disease Brain Is a 68 Amino Acid Metallothionein-Like Protein,” Neuron 7, no. 2 (1991): 337–347.

[140] M. Vašák and G. Meloni, “Chemistry and Biology of Mammalian Metallothioneins,” Journal of Biological Inorganic Chemistry 16, no. 7 (2011): 1067–1078.

[141] F. Reinecke, O. Levanets, Y. Olivier, et al., “Metallothionein Isoform 2A Expression Is Inducible and Protects Against ROS-Mediated Cell Death in Rotenone-Treated HeLa Cells,” Biochemical Journal 395, no. 2 (2006): 405–415.

[142] X. Y. Choo, J. R. Liddell, M. T. Huuskonen, et al., “Cu(II)(atsm) Attenuates Neuroinflammation,” Frontiers in Neuroscience 12 (2018): 668.

[143] S. Lutsenko, E. S. LeShane, and U. Shinde, “Biochemical Basis of Regulation of Human Copper-Transporting ATPases,” Archives of Biochemistry and Biophysics 463, no. 2 (2007): 134–148.

[144] R. Linz and S. Lutsenko, “Copper-Transporting ATPases ATP7A and ATP7B: Cousins, Not Twins,” Journal of Bioenergetics and Biomembranes 39, no. 5–6 (2007): 403–407.

[145] L. Fontaine and J. F. Mercer, “Trafficking of the Copper-ATPases, ATP7A and ATP7B: Role in Copper Homeostasis,” Archives of Biochemistry and Biophysics 463, no. 2 (2007): 149–167.

[146] S. Lutsenko, A. Gupta, J. L. Burkhead, and V. Zuzel, “Cellular Multitasking: The Dual Role of Human Cu-ATPases in Cofactor Delivery and Intracellular Copper Balance,” Archives of Biochemistry and Biophysics 476, no. 1 (2008): 22–32.

[147] P. Gourdon, X. Y. Liu, T. Skjørringe, et al., “Crystal Structure of a Copper-Transporting PIB-Type ATPase,” Nature 475, no. 7354 (2011): 59–64.

[148] F. Arnesano, L. Banci, I. Bertini, et al., “Metallochaperones and Metal-Transporting ATPases: A Comparative Analysis of Sequences and Structures,” Genome Research 12, no. 2 (2002): 255–271.

[149] D. Larin, C. Mekios, K. Das, B. Ross, A. S. Yang, and T. C. Gilliam, “Characterization of the Interaction Between the Wilson and Menkes Disease Proteins and the Cytoplasmic Copper Chaperone, HAH1p,” Journal of Biological Chemistry 274, no. 40 (1999): 28497–28504.

[150] M. DiDonato, H. F. Hsu, S. Narindrasorasak, L. Que, and B. Sarkar, “Copper-Induced Conformational Changes in the N-Terminal Domain of the Wilson Disease Copper-Transporting ATPase,” Biochemistry 39, no. 7 (2000): 1890–1896.

[151] C. H. Yu, N. V. Dolgova, and O. Y. Dmitriev, “Dynamics of the Metal Binding Domains and Regulation of the Human Copper Transporters ATP7B and ATP7A,” IUBMB Life 69, no. 4 (2017): 226–235.

[152] J. Healy and K. Tipton, “Ceruloplasmin and What It Might Do,” Journal of Neural Transmission 114, no. 6 (2007): 777–781.

[153] B. N. Patel, R. J. Dunn, and S. David, “Alternative RNA Splicing Generates a Glycosylphosphatidylinositol-Anchored Form of Ceruloplasmin in Mammalian Brain,” Journal of Biological Chemistry 275, no. 6 (2000): 4305–4310.

[154] G. Vashchenko and R. T. MacGillivray, “Multi-Copper Oxidases and Human Iron Metabolism,” Nutrients 5, no. 7 (2013): 2289–2313.

[155] D. L. de Romaña, O. Manuel, U. Ricardo, and A. Magdalena, “Risks and Benefits of Copper in Light of New Insights of Copper Homeostasis,” Journal of Trace Elements in Medicine and Biology 25, no. 1 (2011): 3–13.

[156] S. I. Cerone, A. S. Sansinanea, S. A. Streitenberger, M. C. Garcia, and N. J. Auza, “Cytochrome c Oxidase, Cu,Zn-Superoxide Dismutase, and Ceruloplasmin Activities in Copper-Deficient Bovines,” Biological Trace Element Research 73, no. 3 (2000): 269–278.

[157] N. E. Hellman and J. D. Gitlin, “Ceruloplasmin Metabolism and Function,” Annual Review of Nutrition 22 (2002): 439–458.

[158] K. Haberska, C. Vaz-Domínguez, A. L. De Lacey, M. Dagys, C. T. Reimann, and S. Shleev, “Direct Electron Transfer Reactions Between Human Ceruloplasmin and Electrodes,” Bioelectrochemistry 76, no. 1–2 (2009): 34–41.

[159] C. Stoj and D. J. Kosman, “Cuprous Oxidase Activity of Yeast Fet3p and Human Ceruloplasmin: Implication for Function,” FEBS Letters 554, no. 3 (2003): 422–426.

[160] G. G. Glenner and C. W. Wong, “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein,” Biochemical and Biophysical Research Communications 120, no. 3 (1984): 885–890.

[161] C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, and K. Beyreuther, “Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome,” PNAS 82, no. 12 (1985): 4245–4249.

[162] J. A. Hardy and G. A. Higgins, “Alzheimer's Disease: The Amyloid Cascade Hypothesis,” Science 256, no. 5054 (1992): 184–185.

[163] D. J. Selkoe and J. Hardy, “The Amyloid Hypothesis of Alzheimer's Disease at 25 Years,” EMBO Molecular Medicine 8, no. 6 (2016): 595–608.

[164] E. S. Musiek and D. M. Holtzman, “Three Dimensions of the Amyloid Hypothesis: Time, Space and 'Wingmen,” Nature Neuroscience 18, no. 6 (2015): 800–806.

[165] E. Delvaux, K. Bentley, V. Stubbs, M. Sabbagh, and P. D. Coleman, “Differential Processing of Amyloid Precursor Protein in Brain and in Peripheral Blood Leukocytes,” Neurobiology of Aging 34, no. 6 (2013): 1680–1686.

[166] M. Korte, U. Herrmann, X. Zhang, and A. Draguhn, “The Role of APP and APLP for Synaptic Transmission, Plasticity, and Network Function: Lessons From Genetic Mouse Models,” Experimental Brain Research 217, no. 3–4 (2012): 435–440.

[167] Y. Senechal, P. H. Kelly, and K. K. Dev, “Amyloid Precursor Protein Knockout Mice Show Age-Dependent Deficits in Passive Avoidance Learning,” Behavioural Brain Research 186, no. 1 (2008): 126–132.

[168] K. S. Orobets and A. L. Karamyshev, “Amyloid Precursor Protein and Alzheimer's Disease,” International Journal of Molecular Sciences 24, no. 19 (2023): 14794.

[169] S. Ring, S. W. Weyer, S. B. Kilian, et al., “The Secreted Beta-Amyloid Precursor Protein Ectodomain APPs Alpha Is Sufficient to Rescue the Anatomical, Behavioral, and Electrophysiological Abnormalities of APP-Deficient Mice,” Journal of Neuroscience 27, no. 29 (2007): 7817–7826.

[170] M. Ohno, E. A. Sametsky, L. H. Younkin, et al., “BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease,” Neuron 41, no. 1 (2004): 27–33.

[171] H. Bukhari, A. Glotzbach, K. Kolbe, G. Leonhardt, C. Loosse, and T. Müller, “Small Things Matter: Implications of APP Intracellular Domain AICD Nuclear Signaling in the Progression and Pathogenesis of Alzheimer's Disease,” Progress in Neurobiology 156 (2017): 189–213.

[172] S. Campioni, B. Mannini, M. Zampagni, et al., “A Causative Link Between the Structure of Aberrant Protein Oligomers and Their Toxicity,” Nature Chemical Biology 6, no. 2 (2010): 140–147.

[173] A. E. Roher, C. L. Esh, T. A. Kokjohn, et al., “Amyloid Beta Peptides in Human Plasma and Tissues and Their Significance for Alzheimer's Disease,” Alzheimer's & Dementia 5, no. 1 (2009): 18–29.

[174] D. Puzzo, L. Privitera, M. Fa, et al., “Endogenous Amyloid-β Is Necessary for Hippocampal Synaptic Plasticity and Memory,” Annals of Neurology 69, no. 5 (2011): 819–830.

[175] C. Ortiz-Sanz, A. Gaminde-Blasco, J. Valero, et al., “Early Effects of Aβ Oligomers on Dendritic Spine Dynamics and Arborization in Hippocampal Neurons,” Frontiers in Synaptic Neuroscience 12 (2020): 2.

[176] W. Cai, L. Li, S. Sang, X. Pan, and C. Zhong, “Physiological Roles of β-Amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology,” Neuroscience Bulletin 39, no. 8 (2023): 1289–1308.

[177] J. A. Duce, A. Tsatsanis, M. A. Cater, et al., “Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease,” Cell 142, no. 6 (2010): 857–867.

[178] K. Honarmand Ebrahimi, C. Dienemann, S. Hoefgen, M. E. Than, P. L. Hagedoorn, and W. R. Hagen, “The Amyloid Precursor Protein (APP) Does Not Have a Ferroxidase Site in Its E2 Domain,” PLoS ONE 8, no. 8 (2013): e72177.

[179] D. Jiang, X. Li, R. Williams, et al., “Ternary Complexes of Iron, Amyloid-Beta, and Nitrilotriacetic Acid: Binding Affinities, Redox Properties, and Relevance to Iron-Induced Oxidative Stress in Alzheimer's Disease,” Biochemistry 48, no. 33 (2009): 7939–7947.

[180] N. G. Nair, G. Perry, M. A. Smith, and V. P. Reddy, “NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-Beta Peptide,” Journal of Alzheimer's Disease 20, no. 1 (2010): 57–66.

[181] S. Boopathi and P. Kolandaivel, “Fe(2+) Binding on Amyloid β-Peptide Promotes Aggregation,” Proteins 84, no. 9 (2016): 1257–1274.

[182] C. Reinhard, S. S. Hébert, and B. De Strooper, “The Amyloid-Beta Precursor Protein: Integrating Structure With Biological Function,” EMBO Journal 24, no. 23 (2005): 3996–4006.

[183] S. O. Dahms, I. Könnig, D. Roeser, et al., “Metal Binding Dictates Conformation and Function of the Amyloid Precursor Protein (APP) E2 Domain,” Journal of Molecular Biology 416, no. 3 (2012): 438–452.

[184] G. K. Kong, J. J. Adams, H. H. Harris, et al., “Structural Studies of the Alzheimer's Amyloid Precursor Protein Copper-Binding Domain Reveal How It Binds Copper Ions,” Journal of Molecular Biology 367, no. 1 (2007): 148–161.

[185] S. K. Singh, V. Balendra, A. A. Obaid, et al., “Copper-Mediated β-Amyloid Toxicity and Its Chelation Therapy in Alzheimer's Disease,” Metallomics 14, no. 6 (2022): mfac018.

[186] E. Falcone and C. Hureau, “Redox Processes in Cu-Binding Proteins: The “In-Between” States in Intrinsically Disordered Peptides,” Chemical Society Reviews 52, no. 19 (2023): 6595–6600.

[187] D. W. Cleveland, S. Y. Hwo, and M. W. Kirschner, “Physical and Chemical Properties of Purified Tau Factor and the Role of Tau in Microtubule Assembly,” Journal of Molecular Biology 116, no. 2 (1977): 227–247.

[188] S. Jeganathan, M. von Bergen, E. M. Mandelkow, and E. Mandelkow, “The Natively Unfolded Character of Tau and Its Aggregation to Alzheimer-Like Paired Helical Filaments,” Biochemistry 47, no. 40 (2008): 10526–10539.

[189] M. D. Mukrasch, S. Bibow, J. Korukottu, et al., “Structural Polymorphism of 441-Residue Tau at Single Residue Resolution,” PLoS Biology 7, no. 2 (2009): e34.

[190] A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, and K. Iqbal, “Hyperphosphorylation Induces Self-Assembly of Tau Into Tangles of Paired Helical Filaments/Straight Filaments,” PNAS 98, no. 12 (2001): 6923–6928.

[191] M. Hong, V. Zhukareva, V. Vogelsberg-Ragaglia, et al., “Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Hereditary FTDP-17,” Science 282, no. 5395 (1998): 1914–1917.

[192] M. Goedert and R. Jakes, “Expression of Separate Isoforms of Human Tau Protein: Correlation With the Tau Pattern in Brain and Effects on Tubulin Polymerization,” EMBO Journal 9, no. 13 (1990): 4225–4230.

[193] J. E. Love, E. J. Hayden, and T. T. Rohn, “Alternative Splicing in Alzheimer's Disease,” Journal of Parkinson's Disease and Alzheimer's Disease 2, no. 2 (2015): 747–758.

[194] R. Brandt and G. Lee, “Functional Organization of Microtubule-Associated Protein Tau. Identification of Regions Which Affect Microtubule Growth, Nucleation, and Bundle Formation In Vitro,” Journal of Biological Chemistry 268, no. 5 (1993): 3414–3419.

[195] D. N. Drechsel, A. A. Hyman, M. H. Cobb, and M. W. Kirschner, “Modulation of the Dynamic Instability of Tubulin Assembly by the Microtubule-Associated Protein Tau,” Molecular Biology of the Cell 3, no. 10 (1992): 1141–1154.

[196] K. A. Butner and M. W. Kirschner, “Tau Protein Binds to Microtubules Through a Flexible Array of Distributed Weak Sites,” Journal of Cell Biology 115, no. 3 (1991): 717–730.

[197] B. L. Goode and S. C. Feinstein, “Identification of a Novel Microtubule Binding and Assembly Domain in the Developmentally Regulated Inter-Repeat Region of Tau,” Journal of Cell Biology 124, no. 5 (1994): 769–782.

[198] H. V. Goodson, C. Valetti, and T. E. Kreis, “Motors and Membrane Traffic,” Current Opinion in Cell Biology 9, no. 1 (1997): 18–28.

[199] S. T. Brady and A. O. Sperry, “Biochemical and Functional Diversity of Microtubule Motors in the Nervous System,” Current Opinion in Neurobiology 5, no. 5 (1995): 551–558.

[200] M. Kolarova, F. García-Sierra, A. Bartos, J. Ricny, and D. Ripova, “Structure and Pathology of Tau Protein in Alzheimer Disease,” International Journal of Alzheimer's Disease 2012 (2012): 731526.

[201] I. Cuchillo-Ibanez, A. Seereeram, H. L. Byers, et al., “Phosphorylation of Tau Regulates Its Axonal Transport by Controlling Its Binding to Kinesin,” FASEB Journal 22, no. 9 (2008): 3186–3195.

[202] K. A. Vossel, K. Zhang, J. Brodbeck, et al., “Tau Reduction Prevents Abeta-Induced Defects in Axonal Transport,” Science 330, no. 6001 (2010): 198.

[203] K. Fujio, M. Sato, T. Uemura, T. Sato, R. Sato-Harada, and A. Harada, “14-3-3 Proteins and Protein Phosphatases Are Not Reduced in Tau-Deficient Mice,” Neuroreport 18, no. 10 (2007): 1049–1052.

[204] D. Saleheen, P. Natarajan, I. M. Armean, et al., “Human Knockouts and Phenotypic Analysis in a Cohort With a High Rate of Consanguinity,” Nature 544, no. 7649 (2017): 235–239.

[205] M. A. Smith, P. L. Harris, L. M. Sayre, and G. Perry, “Iron Accumulation in Alzheimer Disease Is a Source of Redox-Generated Free Radicals,” PNAS 94, no. 18 (1997): 9866–9868.

[206] M. Pérez, J. M. Valpuesta, E. M. de Garcini, et al., “Ferritin Is Associated With the Aberrant Tau Filaments Present in Progressive Supranuclear Palsy,” American Journal of Pathology 152, no. 6 (1998): 1531–1539.

[207] S. Ahmadi, I. I. Ebralidze, Z. She, and H. B. Kraatz, “Electrochemical Studies of Tau Protein-Iron Interactions—Potential Implications for Alzheimer's Disease,” Electrochimica Acta 236 (2017): 384–393.

[208] A. Soragni, B. Zambelli, M. D. Mukrasch, et al., “Structural Characterization of Binding of Cu(II) to Tau Protein,” Biochemistry 47, no. 41 (2008): 10841–10851.

[209] Q. F. Ma, Y. M. Li, J. T. Du, et al., “Binding of Copper (II) Ion to an Alzheimer's Tau Peptide as Revealed by MALDI-TOF MS, CD, and NMR,” Biopolymers 79, no. 2 (2005): 74–85.

[210] L. X. Zhou, J. T. Du, Z. Y. Zeng, et al., “Copper (II) Modulates In Vitro Aggregation of a Tau Peptide,” Peptides 28, no. 11 (2007): 2229–2234.

[211] S. Ahmadi, S. Zhu, R. Sharma, et al., “Aggregation of Microtubule Binding Repeats of Tau Protein Is Promoted by Cu(2),” ACS Omega 4, no. 3 (2019): 5356–5366.

[212] B. H. Hunn, S. J. Cragg, J. P. Bolam, M. G. Spillantini, and R. Wade-Martins, “Impaired Intracellular Trafficking Defines Early Parkinson's Disease,” Trends in Neuroscience 38, no. 3 (2015): 178–188.

[213] J. Burré, M. Sharma, and T. C. Südhof, “Cell Biology and Pathophysiology of α-Synuclein,” Cold Spring Harbor Perspectives in Medicine 8, no. 3 (2018): a024091.

[214] D. F. Clayton and J. M. George, “The Synucleins: A family of Proteins Involved in Synaptic Function, Plasticity, Neurodegeneration and Disease,” Trends in Neuroscience 21, no. 6 (1998): 249–254.

[215] K. Uéda, H. Fukushima, E. Masliah, et al., “Molecular Cloning of cDNA Encoding an Unrecognized Component of Amyloid in Alzheimer Disease,” PNAS 90, no. 23 (1993): 11282–11286.

[216] J. M. George, H. Jin, W. S. Woods, and D. F. Clayton, “Characterization of a Novel Protein Regulated During the Critical Period for Song Learning in the Zebra Finch,” Neuron 15, no. 2 (1995): 361–372.

[217] A. J. Trexler and E. Rhoades, “Alpha-Synuclein Binds Large Unilamellar Vesicles as an Extended Helix,” Biochemistry 48, no. 11 (2009): 2304–2306.

[218] N. Golts, H. Snyder, M. Frasier, C. Theisler, P. Choi, and B. Wolozin, “Magnesium Inhibits Spontaneous and Iron-Induced Aggregation of Alpha-Synuclein,” Journal of Biological Chemistry 277, no. 18 (2002): 16116–16123.

[219] Y. H. Sung, C. Rospigliosi, and D. Eliezer, “NMR Mapping of Copper Binding Sites in Alpha-Synuclein,” Biochimica et Biophysica Acta 1764, no. 1 (2006): 5–12.

[220] A. Binolfi, A. A. Valiente-Gabioud, R. Duran, M. Zweckstetter, C. Griesinger, and C. O. Fernandez, “Exploring the Structural Details of Cu(I) Binding to α-Synuclein by NMR Spectroscopy,” Journal of the American Chemical Society 133, no. 2 (2011): 194–196.

[221] F. Camponeschi, D. Valensin, I. Tessari, et al., “Copper(I)-α-Synuclein Interaction: Structural Description of Two Independent and Competing Metal Binding Sites,” Inorganic Chemistry 52, no. 3 (2013): 1358–1367.

[222] R. Ramis, J. Ortega-Castro, B. Vilanova, M. Adrover, and J. Frau, “Cu(2+), Ca(2+), and Methionine Oxidation Expose the Hydrophobic α-Synuclein NAC Domain,” International Journal of Biological Macromolecules 169 (2021): 251–263.

[223] C. Proukakis, C. G. Dudzik, T. Brier, et al., “A Novel α-Synuclein Missense Mutation in Parkinson Disease,” Neurology 80, no. 11 (2013): 1062–1064.

[224] R. De Ricco, D. Valensin, S. Dell'Acqua, et al., “Remote His50 Acts as a Coordination Switch in the High-Affinity N-Terminal Centered Copper(II) Site of α-Synuclein,” Inorganic Chemistry 54, no. 10 (2015): 4744–4751.

[225] M. A. Wulf, A. Senatore, and A. Aguzzi, “The Biological Function of the Cellular Prion Protein: An Update,” BMC Biology 15, no. 1 (2017): 34.

[226] C. Scheckel and A. Aguzzi, “Prions, Prionoids and Protein Misfolding Disorders,” Nature Reviews Genetics 19, no. 7 (2018): 405–418.

[227] P. K. Baral, J. Yin, A. Aguzzi, and M. N. G. James, “Transition of the Prion Protein From a Structured Cellular Form (PrP(C)) to the Infectious Scrapie Agent (PrP(Sc)),” Protein Science 28, no. 12 (2019): 2055–2063.

[228] B. Caughey, G. S. Baron, B. Chesebro, and M. Jeffrey, “Getting a Grip on Prions: Oligomers, Amyloids, and Pathological Membrane Interactions,” Annual Review of Biochemistry 78 (2009): 177–204.

[229] V. Kovač and V. Č. Šerbec, “Prion Protein: The Molecule of Many Forms and Faces,” International Journal of Molecular Sciences 23, no. 3 (2022): 1232.

[230] K. L. Moya, R. Hässig, C. Créminon, I. Laffont, and L. Di Giamberardino, “Enhanced Detection and Retrograde Axonal Transport of PrPc in Peripheral Nerve,” Journal of Neurochemistry 88, no. 1 (2004): 155–160.

[231] R. Abskharon, F. Wang, A. Wohlkonig, et al., “Structural Evidence for the Critical Role of the Prion Protein Hydrophobic Region in Forming an Infectious Prion,” PLoS Pathogens 15, no. 12 (2019): e1008139.

[232] H. A. Kretzschmar, “Molecular Pathogenesis of Prion Diseases,” European Archives of Psychiatry and Clinical Neuroscience 249, no. suppl 3 (1999): 56–63.

[233] E. Dexter and Q. Kong, “Neuroprotective Effect and Potential of Cellular Prion Protein and Its Cleavage Products for Treatment of Neurodegenerative Disorders Part I. A Literature Review,” Expert Review of Neurotherapeutics 21, no. 9 (2021): 969–982.

[234] A. R. Castle and A. C. Gill, “Physiological Functions of the Cellular Prion Protein,” Frontiers in Molecular Biosciences 4 (2017): 19.

[235] D. R. Borchelt, M. Rogers, N. Stahl, G. Telling, and S. B. Prusiner, “Release of the Cellular Prion Protein From Cultured Cells After Loss of Its Glycoinositol Phospholipid Anchor,” Glycobiology 3, no. 4 (1993): 319–329.

[236] A. Singh, Q. Kong, X. Luo, R. B. Petersen, H. Meyerson, and N. Singh, “Prion Protein (PrP) Knock-Out Mice Show Altered Iron Metabolism: A Functional Role for PrP in Iron Uptake and Transport,” PLoS ONE 4, no. 7 (2009): e6115.

[237] S. Haldar, J. Beveridge, J. Wong, et al., “A Low-Molecular-Weight Ferroxidase Is Increased in the CSF of sCJD Cases: CSF Ferroxidase and Transferrin as Diagnostic Biomarkers for sCJD,” Antioxidants & Redox Signaling 19, no. 14 (2013): 1662–1675.

[238] J. T. Rogers and C. M. Cahill, “Iron-Responsive-Like Elements and Neurodegenerative Ferroptosis,” Learning & Memory 27, no. 9 (2020): 395–413.

[239] L. Ronga, P. Palladino, S. Costantini, et al., “Conformational Diseases and Structure-Toxicity Relationships: Lessons From Prion-Derived Peptides,” Current Protein & Peptide Science 8, no. 1 (2007): 83–90.

[240] G. Salzano, G. Giachin, and G. Legname, “Structural Consequences of Copper Binding to the Prion Protein,” Cells 8, no. 8 (2019): 770.

[241] C. S. Burns, E. Aronoff-Spencer, C. M. Dunham, et al., “Molecular Features of the Copper Binding Sites in the Octarepeat Domain of the Prion Protein,” Biochemistry 41, no. 12 (2002): 3991–4001.

[242] N. Singh, D. Das, A. Singh, and M. L. Mohan, “Prion Protein and Metal Interaction: Physiological and Pathological Implications,” Current Issues in Molecular Biology 12, no. 2 (2010): 99–107.

[243] K. M. Schilling, L. Tao, B. Wu, et al., “Both N-Terminal and C-Terminal Histidine Residues of the Prion Protein Are Essential for Copper Coordination and Neuroprotective Self-Regulation,” Journal of Molecular Biology 432, no. 16 (2020): 4408–4425.

[244] Y. Watanabe, W. Hiraoka, M. Igarashi, et al., “A Novel Copper(II) Coordination at His186 in Full-Length Murine Prion Protein,” Biochemical and Biophysical Research Communications 394, no. 3 (2010): 522–528.

[245] E. W. Martin, A. S. Holehouse, I. Peran, et al., “Valence and Patterning of Aromatic Residues Determine the Phase Behavior of Prion-Like Domains,” Science 367, no. 6478 (2020): 694–699.

[246] M. P. Hughes, L. Goldschmidt, and D. S. Eisenberg, “Prevalence and Species Distribution of the Low-Complexity, Amyloid-Like, Reversible, Kinked Segment Structural Motif in Amyloid-Like Fibrils,” Journal of Biological Chemistry 297, no. 4 (2021): 101194.

[247] M. J. do Amaral, S. Mohapatra, A. R. Passos, et al., “Copper Drives Prion Protein Phase Separation and Modulates Aggregation,” Science Advances 9, no. 44 (2023): eadi7347.

[248] F. D'Egidio, V. Castelli, G. Lombardozzi, F. Ammannito, A. Cimini, and M. d'Angelo, “Therapeutic Advances in Neural Regeneration for Huntington's Disease,” Neural Regeneration Research 19, no. 9 (2024): 1991–1997.

[249] Z. Ortega and J. J. Lucas, “Ubiquitin-Proteasome System Involvement in Huntington's Disease,” Frontiers in Molecular Neuroscience 7 (2014): 77.

[250] H. Tong, T. Yang, S. Xu, et al., “Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies,” International Journal of Molecular Sciences 25, no. 7 (2024): 3845.

[251] A. G. Lobato, N. Ortiz-Vega, Y. Zhu, D. Neupane, K. K. Meier, and R. G. Zhai, “Copper Enhances Aggregational Toxicity of Mutant Huntingtin in a Drosophila Model of Huntington's Disease,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1870, no. 1 (2024): 166928.

[252] J. H. Fox, J. A. Kama, G. Lieberman, et al., “Mechanisms of Copper Ion Mediated Huntington's Disease Progression,” PLoS ONE 2, no. 3 (2007): e334.

[253] R. K. Graham, Y. Deng, E. J. Slow, et al., “Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration due to Mutant Huntingtin,” Cell 125, no. 6 (2006): 1179–1191.

[254] O. D. Jarosińska and S. G. D. Rüdiger, “Molecular Strategies to Target Protein Aggregation in Huntington's Disease,” Frontiers in Molecular Biosciences 8 (2021): 769184.

[255] J. G. Galaz-Montoya, S. H. Shahmoradian, K. Shen, J. Frydman, and W. Chiu, “Cryo-Electron Tomography Provides Topological Insights Into Mutant Huntingtin Exon 1 and PolyQ Aggregates,” Communications Biology 4, no. 1 (2021): 849.

[256] J. H. Fox, T. Connor, M. Stiles, et al., “Cysteine Oxidation Within N-Terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein,” Journal of Biological Chemistry 286, no. 20 (2011): 18320–18330.

[257] H. Long, W. Zhu, L. Wei, and J. Zhao, “Iron Homeostasis Imbalance and Ferroptosis in Brain Diseases,” MedComm 4, no. 4 (2023): e298.

[258] P. Sadhukhan, S. Saha, S. Dutta, S. Mahalanobish, and P. C. Sil, “Nutraceuticals: An Emerging Therapeutic Approach Against the Pathogenesis of Alzheimer's Disease,” Pharmacological Research 129 (2018): 100–114.

[259] A. M. Pisoschi, A. Pop, F. Iordache, L. Stanca, G. Predoi, and A. I. Serban, “Oxidative Stress Mitigation by Antioxidants—An Overview on Their Chemistry and Influences on Health Status,” European Journal of Medicinal Chemistry 209 (2021): 112891.

[260] R. Teschke and A. Eickhoff, “Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, With Comprehensive and Critical Analysis Update,” International Journal of Molecular Sciences 25, no. 9 (2024): 4753.

[261] C. Saporito-Magriñá, R. Musacco-Sebio, J. M. Acosta, et al., “Rat Liver Mitochondrial Dysfunction by Addition of Copper(II) or Iron(III) Ions,” Journal of Inorganic Biochemistry 166 (2017): 5–11.

[262] A. Houldsworth, “Role of Oxidative Stress in Neurodegenerative Disorders: A Review of Reactive Oxygen Species and Prevention by Antioxidants,” Brain Communications 6, no. 1 (2024): fcad356.

[263] I. Villalón-García, S. Povea-Cabello, M. Álvarez-Córdoba, et al., “Vicious Cycle of Lipid Peroxidation and Iron Accumulation in Neurodegeneration,” Neural Regeneration Research 18, no. 6 (2023): 1196–1202.

[264] G. Turgut, I. Akdoğan, E. Adiguzel, and O. Genç, “Effect of Copper Overload Together With Ethanol Uptake on Hippocampal Neurons,” Tohoku Journal of Experimental Medicine 199, no. 4 (2003): 239–245.

[265] L. Behzadfar, M. Abdollahi, O. Sabzevari, et al., “Potentiating Role of Copper on Spatial Memory Deficit Induced by Beta Amyloid and Evaluation of Mitochondrial Function Markers in the Hippocampus of Rats,” Metallomics 9, no. 7 (2017): 969–980.

[266] Q. Wang, J. Sun, T. Chen, et al., “Ferroptosis, Pyroptosis, and Cuproptosis in Alzheimer's Disease,” ACS Chemical Neuroscience 14, no. 19 (2023): 3564–3587.

[267] A. Ahuja, K. Dev, R. S. Tanwar, K. K. Selwal, and P. K. Tyagi, “Copper Mediated Neurological Disorder: Visions Into Amyotrophic Lateral Sclerosis, Alzheimer and Menkes Disease,” Journal of Trace Elements in Medicine and Biology 29 (2015): 11–23.

[268] A. Nobili, E. C. Latagliata, M. T. Viscomi, et al., “Dopamine Neuronal Loss Contributes to Memory and Reward Dysfunction in a Model of Alzheimer's Disease,” Nature Communications 8 (2017): 14727.

[269] Q. Lu, Y. Zhang, C. Zhao, H. Zhang, Y. Pu, and L. Yin, “Copper Induces Oxidative Stress and Apoptosis of Hippocampal Neuron via pCREB/BDNF/and Nrf2/HO-1/NQO1 Pathway,” Journal of Applied Toxicology 42, no. 4 (2022): 694–705.

[270] X. Shen, A. Li, Y. Zhang, et al., “The Effect of Different Intensities of Treadmill Exercise on Cognitive Function Deficit Following a Severe Controlled Cortical Impact in Rats,” International Journal of Molecular Sciences 14, no. 11 (2013): 21598–21612.

[271] G. Gao and Y. Z. Chang, “Iron Metabolism, Redox Balance and Neurological Diseases,” Antioxidants (Basel) 12, no. 9 (2023).

[272] T. R. Hammond, S. E. Marsh, and B. Stevens, “Immune Signaling in Neurodegeneration,” Immunity 50, no. 4 (2019): 955–974.

[273] D. J. DiSabato, N. Quan, and J. P. Godbout, “Neuroinflammation: The Devil Is in the Details,” Journal of Neurochemistry 139, no. suppl 2 (2016): 136–153.

[274] W. Song, Y. Zhang, T. Xu, et al., “Metabolic Reprogramming in Neurodegenerative Diseases: New Insights Into mTOR-Mediated Microglial Polarization,” Journal of Translational Internal Medicine 13, no. 6 (2025): 610–613.

[275] D. M. Norden and J. P. Godbout, “Review: Microglia of the Aged Brain: Primed to be Activated and Resistant to Regulation,” Neuropathology and Applied Neurobiology 39, no. 1 (2013): 19–34.

[276] C. Gao, J. Jiang, Y. Tan, and S. Chen, “Microglia in Neurodegenerative Diseases: Mechanism and Potential Therapeutic Targets,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 359.

[277] J. Wang, Q. Sun, G. Wang, H. Wang, and H. Liu, “The Effects of Blunt Snout Bream (Megalobrama amblycephala) IL-6 Trans-Signaling on Immunity and Iron Metabolism via JAK/STAT3 Pathway,” Developmental and Comparative Immunology 131 (2022): 104372.

[278] W. Zhang, Z. F. Yan, J. H. Gao, et al., “Role and Mechanism of Microglial Activation in Iron-Induced Selective and Progressive Dopaminergic Neurodegeneration,” Molecular Neurobiology 49, no. 3 (2014): 1153–1165.

[279] J. Wang, N. Song, H. Jiang, J. Wang, and J. Xie, “Pro-Inflammatory Cytokines Modulate Iron Regulatory Protein 1 Expression and Iron Transportation Through Reactive Oxygen/Nitrogen Species Production in Ventral Mesencephalic Neurons,” Biochimica et Biophysica Acta 1832, no. 5 (2013): 618–625.

[280] S. K. Ryan, M. Zelic, Y. Han, et al., “Microglia Ferroptosis Is Regulated by SEC24B and Contributes to Neurodegeneration,” Nature Neuroscience 26, no. 1 (2023): 12–26.

[281] A. Kroner, A. D. Greenhalgh, J. G. Zarruk, R. Passos Dos Santos, M. Gaestel, and S. David, “TNF and Increased Intracellular Iron Alter Macrophage Polarization to a Detrimental M1 Phenotype in the Injured Spinal Cord,” Neuron 83, no. 5 (2014): 1098–1116.

[282] J. Lee and D. H. Hyun, “The Interplay Between Intracellular Iron Homeostasis and Neuroinflammation in Neurodegenerative Diseases,” Antioxidants (Basel) 12, no. 4 (2023): 918.

[283] R. J. Ward, D. T. Dexter, and R. R. Crichton, “Iron, Neuroinflammation and Neurodegeneration,” International Journal of Molecular Sciences 23, no. 13 (2022): 7267.

[284] X. Li, X. Zeng, W. Yang, P. Ren, H. Zhai, and H. Yin, “Impacts of Copper Deficiency on Oxidative Stress and Immune Function in Mouse Spleen,” Nutrients 17, no. 1 (2024): 117.

[285] G. Gromadzka, B. Tarnacka, A. Flaga, and A. Adamczyk, “Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications,” International Journal of Molecular Sciences 21, no. 23 (2020): 9259.

[286] A. Pal, I. Rani, A. Pawar, M. Picozza, M. Rongioletti, and R. Squitti, “Microglia and Astrocytes in Alzheimer's Disease in the Context of the Aberrant Copper Homeostasis Hypothesis,” Biomolecules 11, no. 11 (2021): 1598.

[287] R. Coelho, C. A. De Benedictis, A. K. Sauer, et al., “Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer's Disease Pathology,” International Journal of Molecular Sciences 25, no. 3 (2024): 1787.

[288] A. Villarreal, R. Seoane, A. González Torres, et al., “S100B Protein Activates a RAGE-Dependent Autocrine Loop in Astrocytes: Implications for Its Role in the Propagation of Reactive Gliosis,” Journal of Neurochemistry 131, no. 2 (2014): 190–205.

[289] E. Leclerc, E. Sturchler, and S. W. Vetter, “The S100B/RAGE Axis in Alzheimer's Disease,” Cardiovascualr Psychiatry and Neurology 2010 (2010): 539581.

[290] M. García-Domínguez, “Relationship of S100 Proteins With Neuroinflammation,” Biomolecules 15, no. 8 (2025): 1125.

[291] Z. Valiukas, K. Tangalakis, V. Apostolopoulos, and J. Feehan, “Microglial Activation States and Their Implications for Alzheimer's Disease,” Journal of Prevention of Alzheimer's Disease 12, no. 1 (2025): 100013.

[292] M. Azmal, J. K. Paul, F. S. Prima, A. Haque, M. Meem, and A. Ghosh, “Microglial Dysfunction in Alzheimer's Disease: Mechanisms, Emerging Therapies, and Future Directions,” Experimental Neurology 392 (2025): 115374.

[293] T. Jong Huat, J. Camats-Perna, E. A. Newcombe, et al., “The Impact of Astrocytic NF-κB on Healthy and Alzheimer's Disease Brains,” Scientific Reports 14, no. 1 (2024): 14305.

[294] Q. Xue, R. Kang, D. J. Klionsky, D. Tang, J. Liu, and X. Chen, “Copper Metabolism in Cell Death and Autophagy,” Autophagy 19, no. 8 (2023): 2175–2195.

[295] G. Biasiotto, D. Di Lorenzo, S. Archetti, and I. Zanella, “Iron and Neurodegeneration: Is Ferritinophagy the Link?,” Molecular Neurobiology 53, no. 8 (2016): 5542–5574.

[296] Y. Aman, T. Schmauck-Medina, M. Hansen, et al., “Autophagy in Healthy Aging and Disease,” Nature Aging 1, no. 8 (2021): 634–650.

[297] X. Tan, H. Guan, Y. Yang, et al., “Cu(II) Disrupts Autophagy-Mediated Lysosomal Degradation of Oligomeric Aβ in Microglia via mTOR-TFEB Pathway,” Toxicology and Applied Pharmacology 401 (2020): 115090.

[298] N. Santana-Codina, A. Gikandi, and J. D. Mancias, “The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis,” Advances in Experimental Medicine and Biology 1301 (2021): 41–57.

[299] J. D. Mancias, L. Pontano Vaites, S. Nissim, et al., “Ferritinophagy via NCOA4 Is Required for Erythropoiesis and Is Regulated by Iron Dependent HERC2-Mediated Proteolysis,” Elife 4 (2015): e10308.

[300] M. Gao, P. Monian, Q. Pan, W. Zhang, J. Xiang, and X. Jiang, “Ferroptosis Is an Autophagic Cell Death Process,” Cell Research 26, no. 9 (2016): 1021–1032.

[301] A. Cozzi, D. I. Orellana, P. Santambrogio, et al., “Stem Cell Modeling of Neuroferritinopathy Reveals Iron as a Determinant of Senescence and Ferroptosis During Neuronal Aging,” Stem Cell Reports 13, no. 5 (2019): 832–846.

[302] D. Fu, X. Liang, Y. Jiang, et al., “Iron Blocks Autophagic Flux and Induces Autophagosomes Accumulation in Microglia,” Food and Chemical Toxicology 181 (2023): 114054.

[303] J. M. Goodwin, W. E. Dowdle, R. DeJesus, et al., “Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9,” Cell Reports 20, no. 10 (2017): 2341–2356.

[304] S. Dev, S. Asthana, P. Singh, P. Seth, C. Banerjee, and C. K. Mukhopadhyay, “Dopamine Degrades Ferritin by Chaperone-Mediated Autophagy to Elevate Mitochondrial Iron Level in Astroglial Cells,” Free Radical Biology and Medicine 229 (2025): 39–57.

[305] A. Anandhan, H. Rodriguez-Rocha, I. Bohovych, et al., “Overexpression of Alpha-Synuclein at Non-Toxic Levels Increases Dopaminergic Cell Death Induced by Copper Exposure via Modulation of Protein Degradation Pathways,” Neurobiology of Disease 81 (2015): 76–92.

[306] A. Gonzalez-Alcocer, Y. Gopar-Cuevas, A. Soto-Dominguez, et al., “Combined Chronic Copper Exposure and Aging Lead to Neurotoxicity In Vivo,” Neurotoxicology 95 (2023): 181–192.

[307] Y. Zhang, M. Wang, L. Tang, W. Yang, and J. Zhang, “FoxO1 Silencing in Atp7b(-/-) Neural Stem Cells Attenuates High Copper-Induced Apoptosis via Regulation of Autophagy,” Journal of Neurochemistry 168, no. 9 (2024): 2762–2774.

[308] Y. Kim, Y. Lee, M. Choo, N. Yun, J. W. Cho, and Y. J. Oh, “A Surge of Cytosolic Calcium Dysregulates Lysosomal Function and Impairs Autophagy Flux During Cupric Chloride-Induced Neuronal Death,” Journal of Biological Chemistry 300, no. 1 (2024): 105479.

[309] Q. Zhou, Y. Zhang, L. Lu, et al., “Copper Induces Microglia-Mediated Neuroinflammation Through ROS/NF-κB Pathway and Mitophagy Disorder,” Food and Chemical Toxicology 168 (2022): 113369.

[310] A. Picca, J. Faitg, J. Auwerx, L. Ferrucci, and D. D'Amico, “Mitophagy in human Health, Ageing and Disease,” Nature Metabolism 5, no. 12 (2023): 2047–2061.

[311] B. Levine and G. Kroemer, “Biological Functions of Autophagy Genes: A Disease Perspective,” Cell 176, no. 1–2 (2019): 11–42.

[312] J. Doherty and E. H. Baehrecke, “Life, Death and Autophagy,” Nature Cell Biology 20, no. 10 (2018): 1110–1117.

[313] L. Kou, Y. Wang, J. Li, et al., “Mitochondria-Lysosome-Extracellular Vesicles Axis and Nanotheranostics in Neurodegenerative Diseases,” Experimental Neurology 376 (2024): 114757.

[314] S. Tang, A. Fuß, Z. Fattahi, and C. Culmsee, “Drp1 Depletion Protects Against Ferroptotic Cell Death by Preserving Mitochondrial Integrity and Redox Homeostasis,” Cell Death & Disease 15, no. 8 (2024): 626.

[315] M. A. Eldeeb, R. A. Thomas, M. A. Ragheb, A. Fallahi, and E. A. Fon, “Mitochondrial Quality Control in Health and in Parkinson's Disease,” Physiological Reviews 102, no. 4 (2022): 1721–1755.

[316] G. Girolimetti, M. Calcagnile, and C. Bucci, “Potential Role of Membrane Contact Sites in the Dysregulation of the Crosstalk Between Mitochondria and Lysosomes in Alzheimer's Disease,” International Journal of Molecular Sciences 26, no. 20 (2025): 9858.

[317] Z. Wan, J. Xu, Y. Huang, et al., “Elevating Bioavailable Iron Levels in Mitochondria Suppresses the Defective Phenotypes Caused by PINK1 Loss-of-Function in Drosophila melanogaster,” Biochemical and Biophysical Research Communications 532, no. 2 (2020): 285–291.

[318] M. Aschner, A. V. Skalny, R. Lu, et al., “Mitochondrial Pathways of Copper Neurotoxicity: Focus on Mitochondrial Dynamics and Mitophagy,” Frontiers in Molecular Neuroscience 17 (2024): 1504802.

[319] A. Grubman, A. R. White, and J. R. Liddell, “Mitochondrial Metals as a Potential Therapeutic Target in Neurodegeneration,” British Journal of Pharmacology 171, no. 8 (2014): 2159–2173.

[320] H. Z. Long, Y. Cheng, Z. W. Zhou, H. Y. Luo, D. D. Wen, and L. C. Gao, “The Key Roles of Organelles and Ferroptosis in Alzheimer's Disease,” Journal of Neuroscience Research 100, no. 6 (2022): 1257–1280.

[321] H. Li, Y. Cui, Y. Hu, et al., “Mammalian SLC39A13 Promotes ER/Golgi Iron Transport and Iron Homeostasis in Multiple Compartments,” Nature Communications 15, no. 1 (2024): 10838.

[322] G. Joshi, M. E. Bekier, and Y. Wang, “Golgi Fragmentation in Alzheimer's Disease,” Frontiers in Neuroscience 9 (2015): 340.

[323] A. A. Cooper, A. D. Gitler, A. Cashikar, et al., “Alpha-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models,” Science 313, no. 5785 (2006): 324–328.

[324] S. J. Baloyannis, “Golgi Apparatus and Protein Trafficking in Alzheimer's Disease,” Journal of Alzheimer's Disease 42, no. suppl 3 (2014): S153–162.

[325] J. Gale and E. Aizenman, “The Physiological and Pathophysiological Roles of Copper in the Nervous System,” European Journal of Neuroscience 60, no. 1 (2024): 3505–3543.

[326] J. Á. Martínez-Menárguez, M. Tomás, N. Martínez-Martínez, and E. Martínez-Alonso, “Golgi Fragmentation in Neurodegenerative Diseases: Is There a Common Cause?,” Cells 8, no. 7 (2019): 748.

[327] R. O. Saleh, M. S. Jabir, J. S. Mohammed, et al., “Exploring the Endoplasmic Reticulum's Role in Alzheimer's Disease and Its Potential as a Therapeutic Target,” Journal of Biochemical and Molecular Toxicology 39, no. 8 (2025): e70405.

[328] M. Okafor, P. Faller, and N. Vitale, “Cell-Specific Copper Dyshomeostasis Mechanism in Alzheimer's Disease,” Translational Neurodegeneration 14, no. 1 (2025): 42.

[329] X. Bao, L. Chen, H. Yu, et al., “Exosome-Based Modulation of Ferroptosis in Neurological Disorders: Mechanisms, Therapeutic Potential, and Translational Challenges,” Frontiers in Immunology 16 (2025): 1677808.

[330] C. W. Brown, J. J. Amante, P. Chhoy, et al., “Prominin2 Drives Ferroptosis Resistance by Stimulating Iron Export,” Developmental Cell 51, no. 5 (2019): 575–586.e574.

[331] I. Choi, Y. Zhang, S. P. Seegobin, et al., “Microglia Clear Neuron-Released α-Synuclein via Selective Autophagy and Prevent Neurodegeneration,” Nature Communications 11, no. 1 (2020): 1386.

[332] M. K. Boag, A. Roberts, V. N. Uversky, L. Ma, D. R. Richardson, and D. L. Pountney, “Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson's Disease,” International Journal of Molecular Sciences 23, no. 4 (2022): 2378.

[333] L. Jiao, X. Li, Y. Luo, et al., “Iron Metabolism Mediates Microglia Susceptibility in Ferroptosis,” Frontiers in Cellular Neuroscience 16 (2022): 995084.

[334] C. Mukherjee, T. Kling, B. Russo, et al., “Oligodendrocytes Provide Antioxidant Defense Function for Neurons by Secreting Ferritin Heavy Chain,” Cell Metabolism 32, no. 2 (2020): 259–272.e210.

[335] Z. Wang, Y. Zhao, Y. Zhao, Y. Zhang, X. Yao, and R. Hang, “Exosomes Secreted by Macrophages Upon Copper Ion Stimulation Can Promote Angiogenesis,” Materials Science & Engineering C-Materials for Biological Applications 123 (2021): 111981.

[336] M. Basso, S. Pozzi, M. Tortarolo, et al., “Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes: Implications for Disease Spreading and Motor Neuron Pathology in Amyotrophic Lateral Sclerosis,” Journal of Biological Chemistry 288, no. 22 (2013): 15699–15711.

[337] L. J. Vella, A. F. Hill, and L. Cheng, “Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease,” International Journal of Molecular Sciences 17, no. 2 (2016): 173.

[338] X. Ma, Y. Sun, C. Li, et al., “Novel Insights Into DLAT's Role in Alzheimer's Disease-Related Copper Toxicity Through Microglial Exosome Dynamics,” CNS Neuroscience & Therapeutics 30, no. 10 (2024): e70064.

[339] L. Lu, Y. Zhang, W. Shi, et al., “The Role of Autophagy in Copper-Induced Apoptosis and Developmental Neurotoxicity in SH-SY5Y Cells,” Toxics 13, no. 1 (2025): 63.

[340] L. H. You, F. Li, L. Wang, et al., “Brain Iron Accumulation Exacerbates the Pathogenesis of MPTP-Induced Parkinson's Disease,” Neuroscience 284 (2015): 234–246.

[341] W. S. Sarawi, A. M. Alhusaini, L. M. Fadda, et al., “Curcumin and Nano-Curcumin Mitigate Copper Neurotoxicity by Modulating Oxidative Stress, Inflammation, and Akt/GSK-3β Signaling,” Molecules 26, no. 18 (2021): 5591.

[342] S. E. Idrissi, N. Fath, H. Ibork, K. Taghzouti, M. Alamy, and O. Abboussi, “Restraint Stress Exacerbates Apoptosis in a 6-OHDA Animal Model of Parkinson Disease,” Neurotoxicity Research 41, no. 2 (2023): 166–176.

[343] W. Gu, T. Pan, X. Wang, et al., “Sevoflurane Exposure Triggers Ferroptosis of Neuronal Cells Initiated by the Activation of ATM/p53 in the Neonatal Mouse Brain via JNK/p38 MAPK-Mediated Oxidative DNA Damage,” International Immunopharmacology 158 (2025): 114866.

[344] X. Chen, X. Lan, S. Mo, et al., “38 and ERK, but Not JNK, Are Involved in Copper-Induced Apoptosis in Cultured Cerebellar Granule Neurons,” Biochemical and Biophysical Research Communications 379, no. 4 (2009): 944–948.

[345] L. Chen, X. Huan, F. Jia, et al., “Deubiquitylase OTUD3 Mediates Endoplasmic Reticulum Stress Through Regulating Fortilin Stability to Restrain Dopaminergic Neurons Apoptosis,” Antioxidants (Basel) 12, no. 4 (2023): 809.

[346] J. Chakraborty, S. Pakrashi, A. Sarbajna, M. Dutta, and J. Bandyopadhyay, “Quercetin Attenuates Copper-Induced Apoptotic Cell Death and Endoplasmic Reticulum Stress in SH-SY5Y Cells by Autophagic Modulation,” Biological Trace Element Research 200, no. 12 (2022): 5022–5041.

[347] P. Yu, X. Zhang, N. Liu, L. Tang, C. Peng, and X. Chen, “Pyroptosis: Mechanisms and Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 128.

[348] T. Fernandes-Alnemri, J. Wu, J. W. Yu, et al., “The Pyroptosome: A Supramolecular Assembly of ASC Dimers Mediating Inflammatory Cell Death via Caspase-1 Activation,” Cell Death and Differentiation 14, no. 9 (2007): 1590–1604.

[349] J. Shi, Y. Zhao, K. Wang, et al., “Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death,” Nature 526, no. 7575 (2015): 660–665.

[350] W. T. He, H. Wan, L. Hu, et al., “Gasdermin D Is an Executor of Pyroptosis and Required for Interleukin-1β Secretion,” Cell Research 25, no. 12 (2015): 1285–1298.

[351] C. Han, Y. Yang, Q. Guan, et al., “New Mechanism of Nerve Injury in Alzheimer's Disease: Β-Amyloid-Induced Neuronal Pyroptosis,” Journal of Cellular and Molecular Medicine 24, no. 14 (2020): 8078–8090.

[352] R. Gordon, E. A. Albornoz, D. C. Christie, et al., “Inflammasome Inhibition Prevents α-Synuclein Pathology and Dopaminergic Neurodegeneration in Mice,” Science Translational Medicine 10, no. 465 (2018): eaah4066.

[353] Y. Li, J. Li, Q. Yu, L. Ji, and B. Peng, “METTL14 Regulates Microglia/Macrophage Polarization and NLRP3 Inflammasome Activation After Ischemic Stroke by the KAT3B-STING Axis,” Neurobiology of Disease 185 (2023): 106253.

[354] M. J. Zhu, L. Zhang, and C. P. Wang, “Copper Overload Promotes β-Amyloid Induced NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis in Alzheimer's Disease,” Journal of Integrative Neuroscience 23, no. 10 (2024): 194.

[355] Q. Zhou, Y. Zhang, L. Lu, et al., “Upregulation of Postsynaptic cAMP/PKA/CREB Signaling Alleviates Copper(II)-Induced Oxidative Stress and Pyroptosis in MN9D Cells,” Toxicology 494 (2023): 153582.

[356] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, et al., “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death,” Cell 149, no. 5 (2012): 1060–1072.

[357] A. N. von Krusenstiern, R. N. Robson, N. Qian, et al., “Identification of Essential Sites of Lipid Peroxidation in Ferroptosis,” Nature Chemical Biology 19, no. 6 (2023): 719–730.

[358] I. Ingold, C. Berndt, S. Schmitt, et al., “Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis,” Cell 172, no. 3 (2018): 409–422.e421.

[359] X. Zha, X. Liu, M. Wei, et al., “Microbiota-Derived Lysophosphatidylcholine Alleviates Alzheimer's Disease Pathology via Suppressing Ferroptosis,” Cell Metabolism 37, no. 1 (2025): 169–186.e169.

[360] P. Tsvetkov, S. Coy, B. Petrova, et al., “Copper Induces Cell Death by Targeting Lipoylated TCA Cycle Proteins,” Science 375, no. 6586 (2022): 1254–1261.

[361] C. H. Lin, Y. Chin, M. Zhou, R. W. Sobol, M. C. Hung, and M. Tan, “Protein Lipoylation: Mitochondria, Cuproptosis, and Beyond,” Trends in Biochemical Sciences 49, no. 8 (2024): 729–744.

[362] M. B. Dreishpoon, N. R. Bick, B. Petrova, et al., “FDX1 Regulates Cellular Protein Lipoylation Through Direct Binding to LIAS,” Journal of Biological Chemistry 299, no. 9 (2023): 105046.

[363] D. Wang, Z. Tian, P. Zhang, et al., “The Molecular Mechanisms of Cuproptosis and Its Relevance to Cardiovascular Disease,” Biomedicine & Pharmacotherapy 163 (2023): 114830.

[364] M. Huang, Y. Zhang, and X. Liu, “The Mechanism of Cuproptosis in Parkinson's Disease,” Ageing Research Reviews 95 (2024): 102214.

[365] Y. Zhang, Q. Zhou, L. Lu, et al., “Copper Induces Cognitive Impairment in Mice via Modulation of Cuproptosis and CREB Signaling,” Nutrients 15, no. 4 (2023): 972.

[366] C. Guo, P. Wang, M. L. Zhong, et al., “Deferoxamine Inhibits Iron Induced Hippocampal Tau Phosphorylation in the Alzheimer Transgenic Mouse Brain,” Neurochemistry International 62, no. 2 (2013): 165–172.

[367] X. Zeng, H. An, F. Yu, et al., “Benefits of Iron Chelators in the Treatment of Parkinson's Disease,” Neurochemical Research 46, no. 5 (2021): 1239–1251.

[368] S. S. Rao, S. D. Portbury, L. Lago, A. I. Bush, and P. A. Adlard, “The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy,” Journal of Alzheimer's Disease 77, no. 2 (2020): 753–771.

[369] E. Carboni, L. Tatenhorst, L. Tönges, et al., “Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation,” Neuromolecular Medicine 19, no. 2–3 (2017): 309–321.

[370] D. Devos, C. Moreau, J. C. Devedjian, et al., “Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease,” Antioxidants & Redox Signaling 21, no. 2 (2014): 195–210.

[371] D. K. Bailey, W. Clark, and D. J. Kosman, “The Iron Chelator, PBT434, Modulates Transcellular Iron Trafficking in Brain Microvascular Endothelial Cells,” PLoS ONE 16, no. 7 (2021): e0254794.

[372] D. I. Finkelstein, J. L. Billings, P. A. Adlard, et al., “The Novel Compound PBT434 Prevents Iron Mediated Neurodegeneration and Alpha-Synuclein Toxicity in Multiple Models of Parkinson's Disease,” Acta Neuropathologica Communications 5, no. 1 (2017): 53.

[373] L. Kupershmidt, O. Weinreb, T. Amit, S. Mandel, O. Bar-Am, and M. B. Youdim, “Novel Molecular Targets of the Neuroprotective/Neurorescue Multimodal Iron Chelating Drug M30 in the Mouse Brain,” Neuroscience 189 (2011): 345–358.

[374] Q. Wang, X. Zhang, S. Chen, et al., “Prevention of Motor Neuron Degeneration by Novel Iron Chelators in SOD1(G93A) Transgenic Mice of Amyotrophic Lateral Sclerosis,” Neurodegenerative Disease 8, no. 5 (2011): 310–321.

[375] O. Bar-Am, T. Amit, L. Kupershmidt, et al., “Neuroprotective and Neurorestorative Activities of a Novel Iron Chelator-Brain Selective Monoamine Oxidase-A/Monoamine Oxidase-B Inhibitor in Animal Models of Parkinson's Disease and Aging,” Neurobiology of Aging 36, no. 3 (2015): 1529–1542.

[376] L. Chen, L. Xue, J. Zheng, X. Tian, Y. Zhang, and Q. Tong, “PPARß/δ Agonist Alleviates NLRP3 Inflammasome-Mediated Neuroinflammation in the MPTP Mouse Model of Parkinson's Disease,” Behavioural Brain Research 356 (2019): 483–489.

[377] L. Baum and A. Ng, “Curcumin Interaction With Copper and Iron Suggests One Possible Mechanism of Action in Alzheimer's Disease Animal Models,” Journal of Alzheimer's Disease 6, no. 4 (2004): 367–377; discussion 443–369.

[378] L. Li, W. J. Li, X. R. Zheng, et al., “Eriodictyol Ameliorates Cognitive Dysfunction in APP/PS1 Mice by Inhibiting Ferroptosis via Vitamin D Receptor-Mediated Nrf2 Activation,” Molecular Medicine 28, no. 1 (2022): 11.

[379] M. Goujon, Z. Liang, D. Soriano-Castell, A. Currais, P. Maher, et al., “The Neuroprotective Flavonoids Sterubin and Fisetin Maintain Mitochondrial Health Under Oxytotic/Ferroptotic Stress and Improve Bioenergetic Efficiency in HT22 Neuronal Cells.” Antioxidants (Basel) 13, no. 4 (2024): 460.

[380] X. Li, J. Chen, W. Feng, et al., “Berberine Ameliorates Iron Levels and Ferroptosis in the Brain of 3 × Tg-AD Mice,” Phytomedicine 118 (2023): 154962.

[381] M. Jahanshahi, M. Khalili, and A. Margedari, “Naringin Chelates Excessive Iron and Prevents the Formation of Amyloid-Beta Plaques in the Hippocampus of Iron-Overloaded Mice,” Frontiers in Pharmacology 12 (2021): 651156.

[382] C. B. Hu, H. Jiang, Y. Yang, et al., “DL-3-n-Butylphthalide Alleviates Motor Disturbance by Suppressing Ferroptosis in a Rat Model of Parkinson's Disease,” Neural Regeneration Research 18, no. 1 (2023): 194–199.

[383] Z. H. Lin, Y. Liu, N. J. Xue, et al., “Quercetin Protects Against MPP(+)/MPTP-Induced Dopaminergic Neuron Death in Parkinson's Disease by Inhibiting Ferroptosis,” Oxidative Medicine and Cellular Longevity 2022 (2022): 7769355.

[384] J. Zhao, L. Xu, Q. Liang, et al., “Metal Chelator EGCG Attenuates Fe(III)-Induced Conformational Transition of α-Synuclein and Protects AS-PC12 Cells Against Fe(III)-Induced Death,” Journal of Neurochemistry 143, no. 1 (2017): 136–146.

[385] S. McKenzie-Nickson, J. Chan, K. Perez, et al., “Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies,” ACS Chemical Neuroscience 9, no. 11 (2018): 2731–2740.

[386] L. M. Guthrie, S. Soma, S. Yuan, et al., “Elesclomol Alleviates Menkes Pathology and Mortality by Escorting Cu to Cuproenzymes in Mice,” Science 368, no. 6491 (2020): 620–625.

[387] P. Soczewka, D. Tribouillard-Tanvier, J. P. di Rago, T. Zoladek, and J. Kaminska, “Targeting Copper Homeostasis Improves Functioning of vps13Δ Yeast Mutant Cells, a Model of VPS13-Related Diseases,” International Journal of Molecular Sciences 22, no. 5 (2021): 2248.

[388] R. A. Cherny, C. S. Atwood, M. E. Xilinas, et al., “Treatment With a Copper-Zinc Chelator Markedly and Rapidly Inhibits Beta-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice,” Neuron 30, no. 3 (2001): 665–676.

[389] K. M. Davies, J. F. Mercer, N. Chen, and K. L. Double, “Copper Dyshomoeostasis in Parkinson's Disease: Implications for Pathogenesis and Indications for Novel Therapeutics,” Clinical Science (London) 130, no. 8 (2016): 565–574.

[390] T. Nguyen, A. Hamby, and S. M. Massa, “Clioquinol Down-Regulates Mutant Huntingtin Expression In Vitro and Mitigates Pathology in a Huntington's Disease Mouse Model,” PNAS 102, no. 33 (2005): 11840–11845.

[391] B. Y. Choi, B. G. Jang, J. H. Kim, et al., “Copper/Zinc Chelation by Clioquinol Reduces Spinal Cord White Matter Damage and Behavioral Deficits in a Murine MOG-Induced Multiple Sclerosis Model,” Neurobiology of Disease 54 (2013): 382–391.

[392] K. J. Barnham and A. I. Bush, “Biological Metals and Metal-Targeting Compounds in Major Neurodegenerative Diseases,” Chemical Society Reviews 43, no. 19 (2014): 6727–6749.

[393] R. A. Cherny, S. Ayton, D. I. Finkelstein, A. I. Bush, G. McColl, and S. M. Massa, “PBT2 Reduces Toxicity in a C. elegans Model of PolyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease,” Journal of Huntington's Disease 1, no. 2 (2012): 211–219.

[394] D. S. Cukierman, A. B. Pinheiro, S. L. Castiñeiras-Filho, et al., “A Moderate Metal-Binding Hydrazone Meets the Criteria for a Bioinorganic Approach Towards Parkinson's Disease: Therapeutic Potential, Blood-Brain Barrier Crossing Evaluation and Preliminary Toxicological Studies,” Journal of Inorganic Biochemistry 170 (2017): 160–168.

[395] R. Squitti, P. M. Rossini, E. Cassetta, et al., “D-Penicillamine Reduces Serum Oxidative Stress in Alzheimer's Disease Patients,” European Journal of Clinical Investigation 32, no. 1 (2002): 51–59.

[396] J. Zhao, Q. Shi, H. Tian, et al., “TDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimer's Disease Mouse Models,” ACS Chemical Neuroscience 12, no. 1 (2021): 140–149.

[397] L. W. Hung, V. L. Villemagne, L. Cheng, et al., “The Hypoxia Imaging Agent CuII(atsm) Is Neuroprotective and Improves Motor and Cognitive Functions in Multiple Animal Models of Parkinson's Disease,” Journal of Experimental Medicine 209, no. 4 (2012): 837–854.

[398] B. R. Roberts, N. K. Lim, E. J. McAllum, et al., “Oral Treatment With Cu(II)(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis,” Journal of Neuroscience 34, no. 23 (2014): 8021–8031.

[399] E. Tokuda and Y. Furukawa, “Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis With SOD1 Mutations,” International Journal of Molecular Sciences 17, no. 5 (2016): 636.

[400] I. Mohr, H. Bourhis, F. Woimant, et al., “Experience on Switching Trientine Formulations in Wilson Disease: Efficacy and Safety After Initiation of TETA 4HCl as Substitute for TETA 2HCl,” Journal of Gastroenterology and Hepatology 38, no. 2 (2023): 219–224.

[401] S. Nomura, S. Nozaki, T. Hamazaki, et al., “PET Imaging Analysis With 64Cu in Disulfiram Treatment for Aberrant Copper Biodistribution in Menkes Disease Mouse Model,” Journal of Nuclear Medicine 55, no. 5 (2014): 845–851.

[402] F. T. Kirk, D. E. Munk, E. S. Swenson, et al., “Effects of Tetrathiomolybdate on Copper Metabolism in Healthy Volunteers and in Patients With Wilson Disease,” Journal of Hepatology 80, no. 4 (2024): 586–595.

[403] K. H. Weiss, A. Członkowska, P. Hedera, and P. Ferenci, “WTX101 – An Investigational Drug for the Treatment of Wilson Disease,” Expert Opinion on Investigational Drugs 27, no. 6 (2018): 561–567.

[404] A. S. DeToma, J. S. Choi, J. J. Braymer, and M. H. Lim, “Myricetin: A Naturally Occurring Regulator of Metal-Induced Amyloid-β Aggregation and Neurotoxicity,” Chembiochem 12, no. 8 (2011): 1198–1201.

[405] L. Zhao, J. L. Wang, Y. R. Wang, and X. Z. Fa, “Apigenin Attenuates Copper-Mediated β-Amyloid Neurotoxicity Through Antioxidation, Mitochondrion Protection and MAPK Signal Inactivation in an AD Cell Model,” Brain Research 1492 (2013): 33–45.

[406] Y. Teng, J. Zhao, L. Ding, Y. Ding, P. Zhou, et al., “Complex of EGCG With Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein.” Molecules 24, no. 16 (2019): 2940.

[407] Y. Zeng, W. Guo, G. Xu, et al., “Xyloketal-Derived Small Molecules Show Protective Effect by Decreasing Mutant Huntingtin Protein Aggregates in Caenorhabditis elegans Model of Huntington's Disease,” Drug Design, Development and Therapy 10 (2016): 1443–1451.

[408] V. K. Wong, A. G. Wu, J. R. Wang, L. Liu, and B. Y. Law, “Neferine Attenuates the Protein Level and Toxicity of Mutant Huntingtin in PC-12 Cells via Induction of Autophagy,” Molecules 20, no. 3 (2015): 3496–3514.

[409] W. Wang, F. Sun, Y. An, et al., “Morroniside Protects human Neuroblastoma SH-SY5Y Cells Against Hydrogen Peroxide-Induced Cytotoxicity,” European Journal of Pharmacology 613, no. 1–3 (2009): 19–23.

[410] X. Y. Zhang, X. Wang, T. Ye, et al., “Network Pharmacology-Based Approach to Understand the Effect and Mechanism of Chrysophanol Against Cognitive Impairment in Wilson Disease,” Metabolic Brain Disease 39, no. 1 (2024): 89–99.

[411] S. Yamamoto, C. Sakemoto, K. Iwasa, K. Maruyama, K. Shimizu, and K. Yoshikawa, “Ursolic Acid Treatment Suppresses Cuprizone-Induced Demyelination and Motor Dysfunction via Upregulation of IGF-1,” Journal of Pharmacological Sciences 144, no. 3 (2020): 119–122.

[412] J. M. Ringman, S. A. Frautschy, E. Teng, et al., “Oral Curcumin for Alzheimer's Disease: Tolerability and Efficacy in a 24-Week Randomized, Double Blind, Placebo-Controlled Study,” Alzheimer's Research & Therapy 4, no. 5 (2012): 43.

[413] S. Ayton, D. Barton, B. Brew, et al., “Deferiprone in Alzheimer Disease: A Randomized Clinical Trial,” JAMA Neurology 82, no. 1 (2025): 11–18.

[414] A. Martin-Bastida, R. J. Ward, R. Newbould, et al., “Brain Iron Chelation by Deferiprone in a Phase 2 Randomised Double-Blinded Placebo Controlled Clinical Trial in Parkinson's Disease,” Scientific Reports 7, no. 1 (2017): 1398.

[415] D. Devos, J. Labreuche, O. Rascol, et al., “Trial of Deferiprone in Parkinson's Disease,” New England Journal of Medicine 387, no. 22 (2022): 2045–2055.

[416] L. Lannfelt, K. Blennow, H. Zetterberg, et al., “Safety, Efficacy, and Biomarker Findings of PBT2 in Targeting Abeta as a Modifying Therapy for Alzheimer's Disease: A Phase IIa, Double-Blind, Randomised, Placebo-Controlled Trial,” Lancet Neurology 7, no. 9 (2008): 779–786.

[417] N. G. Faux, C. W. Ritchie, A. Gunn, et al., “PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses,” Journal of Alzheimer's Disease 20, no. 2 (2010): 509–516.

[418] G. J. Brewer, F. Askari, M. T. Lorincz, et al., “Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: IV. Comparison of Tetrathiomolybdate and Trientine in a Double-Blind Study of Treatment of the Neurologic Presentation of Wilson Disease,” Archives of Neurology 63, no. 4 (2006): 521–527.

[419] K. H. Weiss, F. K. Askari, A. Czlonkowska, et al., “Bis-Choline Tetrathiomolybdate in Patients With Wilson's Disease: An Open-Label, Multicentre, Phase 2 Study,” Lancet Gastroenterology and Hepatology 2, no. 12 (2017): 869–876.

[420] D. Bega, K. Weiss, M. Schilsky, and A. Czlonkowska, “Efficacy and Safety of ALXN1840 Versus Standard of Care in Wilson Disease: Primary Results From an Ongoing Phase 3, Randomized, Controlled, Rater-Blinded Trial,” in AAN Annual Meeting, Boston, MA (2023).

[421] Investigators, Huntington Study Group Reach2HD. “Safety, Tolerability, and Efficacy of PBT2 in Huntington's Disease: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial.” Lancet Neurology 14, no. 1 (2015): 39–47.

[422] Alzheimer's Association. “2023 Alzheimer's Disease Facts and Figures.” Alzheimer's & Dementia 19, no. 4 (2023): 1598–1695.

[423] Y. A. Martens, N. Zhao, C. C. Liu, et al., “ApoE Cascade Hypothesis in the Pathogenesis of Alzheimer's Disease and Related Dementias,” Neuron 110, no. 8 (2022): 1304–1317.

[424] R. Vassar, B. D. Bennett, S. Babu-Khan, et al., “Beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE,” Science 286, no. 5440 (1999): 735–741.

[425] N. Tang and K. P. Kepp, “Aβ42/Aβ40 Ratios of Presenilin 1 Mutations Correlate With Clinical Onset of Alzheimer's Disease,” Journal of Alzheimer's Disease 66, no. 3 (2018): 939–945.

[426] A. R. Ladiwala, J. Litt, R. S. Kane, et al., “Conformational Differences Between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity,” Journal of Biological Chemistry 287, no. 29 (2012): 24765–24773.

[427] S. C. Drew, C. J. Noble, C. L. Masters, G. R. Hanson, and K. J. Barnham, “Pleomorphic Copper Coordination by Alzheimer's Disease Amyloid-Beta Peptide,” Journal of the American Chemical Society 131, no. 3 (2009): 1195–1207.

[428] S. L. Shammas, G. A. Garcia, S. Kumar, et al., “A Mechanistic Model of Tau Amyloid Aggregation Based on Direct Observation of Oligomers,” Nature Communications 6 (2015): 7025.

[429] I. Ferrer, I. López-González, M. Carmona, et al., “Glial and Neuronal Tau Pathology in Tauopathies: Characterization of Disease-Specific Phenotypes and Tau Pathology Progression,” Journal of Neuropathology and Experimental Neurology 73, no. 1 (2014): 81–97.

[430] F. Clavaguera, T. Bolmont, R. A. Crowther, et al., “Transmission and Spreading of Tauopathy in Transgenic Mouse Brain,” Nature Cell Biology 11, no. 7 (2009): 909–913.

[431] H. N. Dawson, A. Ferreira, M. V. Eyster, N. Ghoshal, L. I. Binder, and M. P. Vitek, “Inhibition of Neuronal Maturation in Primary Hippocampal Neurons From Tau Deficient Mice,” Journal of Cell Science 114, no. pt 6 (2001): 1179–1187.

[432] S. S. Rao and P. A. Adlard, “Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration,” Frontiers in Molecular Neuroscience 11 (2018): 276.

[433] N. D. Telling, J. Everett, J. F. Collingwood, et al., “Iron Biochemistry Is Correlated With Amyloid Plaque Morphology in an Established Mouse Model of Alzheimer's Disease,” Cell Chemical Biology 24, no. 10 (2017): 1205–1215.e1203.

[434] J. Everett, J. F. Collingwood, V. Tjendana-Tjhin, et al., “Nanoscale Synchrotron X-Ray Speciation of Iron and Calcium Compounds in Amyloid Plaque Cores From Alzheimer's Disease Subjects,” Nanoscale 10, no. 25 (2018): 11782–11796.

[435] J. Everett, J. Brooks, F. Lermyte, et al., “Iron Stored in Ferritin Is Chemically Reduced in the Presence of Aggregating Aβ(1-42),” Scientific Reports 10, no. 1 (2020): 10332.

[436] K. Goozee, P. Chatterjee, I. James, et al., “Elevated Plasma Ferritin in Elderly Individuals With High Neocortical Amyloid-β Load,” Molecular Psychiatry 23, no. 8 (2018): 1807–1812.

[437] S. Petralla, L. Saveleva, K. M. Kanninen, et al., “Increased Expression of Transferrin Receptor 1 in the Brain Cortex of 5xFAD Mouse Model of Alzheimer's Disease Is Associated With Activation of HIF-1 Signaling Pathway,” Molecular Neurobiology 61, no. 9 (2024): 6383–6394.

[438] W. D. Bao, P. Pang, X. T. Zhou, et al., “Loss of Ferroportin Induces Memory Impairment by Promoting Ferroptosis in Alzheimer's Disease,” Cell Death and Differentiation 28, no. 5 (2021): 1548–1562.

[439] B. X. Wong, A. Tsatsanis, L. Q. Lim, P. A. Adlard, A. I. Bush, and J. A. Duce, “β-Amyloid Precursor Protein Does Not Possess Ferroxidase Activity but Does Stabilize the Cell Surface Ferrous Iron Exporter Ferroportin,” PLoS ONE 9, no. 12 (2014): e114174.

[440] A. Tsatsanis, B. X. Wong, A. P. Gunn, et al., “Amyloidogenic Processing of Alzheimer's Disease β-Amyloid Precursor Protein Induces Cellular Iron Retention,” Molecular Psychiatry 25, no. 9 (2020): 1958–1966.

[441] R. C. McCarthy, J. C. Sosa, A. M. Gardeck, A. S. Baez, C. H. Lee, and M. Wessling-Resnick, “Inflammation-Induced Iron Transport and Metabolism by Brain Microglia,” Journal of Biological Chemistry 293, no. 20 (2018): 7853–7863.

[442] I. C. Nnah, C. H. Lee, and M. Wessling-Resnick, “Iron Potentiates Microglial Interleukin-1β Secretion Induced by Amyloid-β,” Journal of Neurochemistry 154, no. 2 (2020): 177–189.

[443] B. Kenkhuis, A. Somarakis, L. de Haan, et al., “Iron Loading Is a Prominent Feature of Activated Microglia in Alzheimer's Disease Patients,” Acta Neuropathologica Communications 9, no. 1 (2021): 27.

[444] N. Majerníková, A. Marmolejo-Garza, C. S. Salinas, et al., “The Link Between Amyloid β and Ferroptosis Pathway in Alzheimer's Disease Progression,” Cell Death & Disease 15, no. 10 (2024): 782.

[445] M. A. Thorwald, J. A. Godoy-Lugo, G. Garcia, et al., “Iron-Associated Lipid Peroxidation in Alzheimer's Disease Is Increased in Lipid Rafts With Decreased Ferroptosis Suppressors, Tested by Chelation in Mice,” Alzheimer's & Dementia 21, no. 1 (2025): e14541.

[446] M. A. Khan, “Iron Responsive Elements mRNA Regulate Alzheimer's Amyloid Precursor Protein Translation Through Iron Sensing,” Frontiers in Aging Neuroscience 17 (2025): 1483913.

[447] P. Lei, S. Ayton, D. I. Finkelstein, et al., “Tau Deficiency Induces Parkinsonism With Dementia by Impairing APP-Mediated Iron Export,” Nature Medicine 18, no. 2 (2012): 291–295.

[448] X. Li, P. Lei, Q. Tuo, et al., “Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau,” Neurotherapeutics 12, no. 4 (2015): 862–873.

[449] P. J. Derry, M. L. Hegde, G. R. Jackson, et al., “Revisiting the Intersection of Amyloid, Pathologically Modified Tau and Iron in Alzheimer's Disease From a Ferroptosis Perspective,” Progress in Neurobiology 184 (2020): 101716.

[450] Y. Liu, Y. Chen, and K. Fukui, “Oxidative Stress Induces Tau Hyperphosphorylation via MARK Activation in Neuroblastoma N1E-115 Cells,” Journal of Clinical Biochemistry and Nutrition 73, no. 1 (2023): 24–33.

[451] C. Chahla, H. Kovacic, L. Ferhat, and L. Leloup, “Pathological Impact of Redox Post-Translational Modifications,” Antioxidants & Redox Signaling 41, no. 1–3 (2024): 152–180.

[452] L. Wang, Y. L. Yin, X. Z. Liu, et al., “Current Understanding of Metal Ions in the Pathogenesis of Alzheimer's Disease,” Translational Neurodegeneration 9 (2020): 10.

[453] X. Huang, R. D. Moir, R. E. Tanzi, A. I. Bush, and J. T. Rogers, “Redox-Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology,” Annals of the New York Academy of Sciences 1012 (2004): 153–163.

[454] D. D. Li, W. Zhang, Z. Y. Wang, and P. Zhao, “Serum Copper, Zinc, and Iron Levels in Patients With Alzheimer's Disease: A Meta-Analysis of Case-Control Studies,” Frontiers in Aging Neuroscience 9 (2017): 300.

[455] Z. D. Liang, W. B. Tsai, M. Y. Lee, N. Savaraj, and M. T. Kuo, “Specificity Protein 1 (SP1) Oscillation Is Involved in Copper Homeostasis Maintenance by Regulating Human High-Affinity Copper Transporter 1 Expression,” Molecular Pharmacology 81, no. 3 (2012): 455–464.

[456] M. A. Christensen, W. Zhou, H. Qing, A. Lehman, S. Philipsen, and W. Song, “Transcriptional Regulation of BACE1, the Beta-Amyloid Precursor Protein Beta-Secretase, by Sp1,” Molecular and Cellular Biology 24, no. 2 (2004): 865–874.

[457] I. S. Song, H. H. Chen, I. Aiba, et al., “Transcription Factor Sp1 Plays an Important Role in the Regulation of Copper Homeostasis in Mammalian Cells,” Molecular Pharmacology 74, no. 3 (2008): 705–713.

[458] M. A. Cater, K. T. McInnes, Q. X. Li, et al., “Intracellular Copper Deficiency Increases Amyloid-Beta Secretion by Diverse Mechanisms,” Biochemical Journal 412, no. 1 (2008): 141–152.

[459] Y. H. Hung, E. L. Robb, I. Volitakis, et al., “Paradoxical Condensation of Copper With Elevated Beta-Amyloid in Lipid Rafts Under Cellular Copper Deficiency Conditions: Implications for Alzheimer Disease,” Journal of Biological Chemistry 284, no. 33 (2009): 21899–21907.

[460] R. Squitti, M. Ventriglia, I. Simonelli, et al., “Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants,” Biomolecules 11, no. 7 (2021): 960.

[461] G. Multhaup, A. Schlicksupp, L. Hesse, et al., “The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I),” Science 271, no. 5254 (1996): 1406–1409.

[462] J. Everett, F. Lermyte, J. Brooks, et al., “Biogenic Metallic Elements in the Human Brain?,” Science Advances 7, no. 24 (2021): eabf6707.

[463] X. Huang, M. P. Cuajungco, C. S. Atwood, et al., “Cu(II) Potentiation of Alzheimer Abeta Neurotoxicity. Correlation With Cell-Free Hydrogen Peroxide Production and Metal Reduction,” Journal of Biological Chemistry 274, no. 52 (1999): 37111–37116.

[464] X. Huang, “A Concise Review on Oxidative Stress-Mediated Ferroptosis and Cuproptosis in Alzheimer's Disease,” Cells 12, no. 10 (2023): 1369.

[465] H. Wesseling, W. Mair, M. Kumar, et al., “Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease,” Cell 183, no. 6 (2020): 1699–1713.e1613.

[466] I. Singh, A. P. Sagare, M. Coma, et al., “Low Levels of Copper Disrupt Brain Amyloid-β Homeostasis by Altering Its Production and Clearance,” PNAS 110, no. 36 (2013): 14771–14776.

[467] G. Bjørklund, M. Dadar, G. Anderson, S. Chirumbolo, and M. Maes, “Preventive Treatments to Slow Substantia Nigra Damage and Parkinson's Disease Progression: A Critical Perspective Review,” Pharmacological Research 161 (2020): 105065.

[468] E. Tolosa, A. Garrido, S. W. Scholz, and W. Poewe, “Challenges in the Diagnosis of Parkinson's Disease,” Lancet Neurology 20, no. 5 (2021): 385–397.

[469] A. Rasool, R. Manzoor, K. Ullah, et al., “Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies,” CNS & Neurological Disorders - Drug Targets 23, no. 7 (2024): 852–864.

[470] F. De Lazzari, L. Bubacco, A. J. Whitworth, and M. Bisaglia, “Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson's Disease,” Aging and Disease 9, no. 4 (2018): 716–728.

[471] M. Bisaglia and L. Bubacco, “Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?,” Biomolecules 10, no. 2 (2020): 195.

[472] P. Calabresi, A. Mechelli, G. Natale, L. Volpicelli-Daley, G. Di Lazzaro, and V. Ghiglieri, “Alpha-Synuclein in Parkinson's Disease and Other Synucleinopathies: From Overt Neurodegeneration Back to Early Synaptic Dysfunction,” Cell Death & Disease 14, no. 3 (2023): 176.

[473] S. Mohammadi and S. Ghaderi, “Parkinson's Disease and Parkinsonism Syndromes: Evaluating Iron Deposition in the Putamen Using Magnetic Susceptibility MRI Techniques—A Systematic Review and Literature Analysis,” Heliyon 10, no. 7 (2024): e27950.

[474] J. Salazar, N. Mena, S. Hunot, et al., “Divalent Metal Transporter 1 (DMT1) Contributes to Neurodegeneration in Animal Models of Parkinson's Disease,” PNAS 105, no. 47 (2008): 18578–18583.

[475] J. Howitt, U. Putz, J. Lackovic, et al., “Divalent Metal Transporter 1 (DMT1) Regulation by Ndfip1 Prevents Metal Toxicity in Human Neurons,” PNAS 106, no. 36 (2009): 15489–15494.

[476] T. Liang, S. X. Yang, C. Qian, et al., “HMGB1 Mediates Inflammation-Induced DMT1 Increase and Dopaminergic Neurodegeneration in the Early Stage of Parkinsonism,” Molecular Neurobiology 61, no. 4 (2024): 2006–2020.

[477] A. A. Raha, A. Biswas, J. Henderson, et al., “Interplay of Ferritin Accumulation and Ferroportin Loss in Ageing Brain: Implication for Protein Aggregation in Down Syndrome Dementia, Alzheimer's, and Parkinson's Diseases,” International Journal of Molecular Sciences 23, no. 3 (2022): 1060.

[478] P. R. Angelova, M. L. Choi, A. V. Berezhnov, et al., “Alpha Synuclein Aggregation Drives Ferroptosis: An Interplay of Iron, Calcium and Lipid Peroxidation,” Cell Death and Differentiation 27, no. 10 (2020): 2781–2796.

[479] Z. D. Zhou, Y. H. Lan, E. K. Tan, and T. M. Lim, “Iron Species-Mediated Dopamine Oxidation, Proteasome Inhibition, and Dopaminergic Cell Demise: Implications for Iron-Related Dopaminergic Neuron Degeneration,” Free Radical Biology and Medicine 49, no. 12 (2010): 1856–1871.

[480] C. Andersen, A. L. Grønnemose, J. N. Pedersen, et al., “Lipid Peroxidation Products HNE and ONE Promote and Stabilize Alpha-Synuclein Oligomers by Chemical Modifications,” Biochemistry 60, no. 47 (2021): 3644–3658.

[481] B. Chen, X. Wen, H. Jiang, J. Wang, N. Song, and J. Xie, “Interactions Between Iron and α-Synuclein Pathology in Parkinson's Disease,” Free Radical Biology and Medicine 141 (2019): 253–260.

[482] Z. Zeng, Y. Cen, L. Xiong, G. Hong, Y. Luo, and X. Luo, “Dietary Copper Intake and Risk of Parkinson's Disease: A Cross-Sectional Study,” Biological Trace Element Research 202, no. 3 (2024): 955–964.

[483] K. M. Davies, S. Bohic, A. Carmona, et al., “Copper Pathology in Vulnerable Brain Regions in Parkinson's Disease,” Neurobiology of Aging 35, no. 4 (2014): 858–866.

[484] L. Mezzaroba, D. F. Alfieri, A. N. Colado Simão, and E. M. Vissoci Reiche, “The Role of Zinc, Copper, Manganese and Iron in Neurodegenerative Diseases,” Neurotoxicology 74 (2019): 230–241.

[485] M. C. Boll, M. Alcaraz-Zubeldia, S. Montes, and C. Rios, “Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NO(x) Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases,” Neurochemical Research 33, no. 9 (2008): 1717–1723.

[486] I. Hozumi, T. Hasegawa, A. Honda, et al., “Patterns of Levels of Biological Metals in CSF Differ Among Neurodegenerative Diseases,” Journal of the Neurological Sciences 303, no. 1-2 (2011): 95–99.

[487] S. Li, Y. Liu, S. Lu, et al., “A Crazy Trio in Parkinson's Disease: Metabolism Alteration, α-Synuclein Aggregation, and Oxidative Stress,” Molecular and Cellular Biochemistry 480, no. 1 (2024): 139–157.

[488] A. Gonzalez-Alcocer, A. P. Duarte-Jurado, A. Soto-Dominguez, et al., “Unscrambling the Role of Redox-Active Biometals in Dopaminergic Neuronal Death and Promising Metal Chelation-Based Therapy for Parkinson's Disease,” International Journal of Molecular Sciences 24, no. 2 (2023): 1256.

[489] S. Ayton, P. Lei, J. A. Duce, et al., “Ceruloplasmin Dysfunction and Therapeutic Potential for Parkinson Disease,” Annals of Neurology 73, no. 4 (2013): 554–559.

[490] E. Monzani, S. Nicolis, S. Dell'Acqua, et al., “Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases,” Angewandte Chemie 58, no. 20 (2019): 6512–6527.

[491] S. Pyatha, H. Kim, D. Lee, K. Kim, et al., “Association Between Heavy Metal Exposure and Parkinson's Disease: A Review of the Mechanisms Related to Oxidative Stress.” Antioxidants (Basel) 11, no. 12 (2022): 2467.

[492] R. M. Rasia, C. W. Bertoncini, D. Marsh, et al., “Structural Characterization of Copper(II) Binding to Alpha-Synuclein: Insights Into the Bioinorganic Chemistry of Parkinson's Disease,” PNAS 102, no. 12 (2005): 4294–4299.

[493] S. Dell'Acqua, V. Pirota, C. Anzani, et al., “Reactivity of Copper-α-Synuclein Peptide Complexes Relevant to Parkinson's Disease,” Metallomics 7, no. 7 (2015): 1091–1102.

[494] I. Zerr, A. Ladogana, S. Mead, P. Hermann, G. Forloni, and B. S. Appleby, “Creutzfeldt-Jakob Disease and Other Prion Diseases,” Nature Reviews Disease Primers 10, no. 1 (2024): 14.

[495] P. Hermann, B. Appleby, J. P. Brandel, et al., “Biomarkers and Diagnostic Guidelines for Sporadic Creutzfeldt-Jakob Disease,” Lancet Neurology 20, no. 3 (2021): 235–246.

[496] M. K. Sandberg, H. Al-Doujaily, B. Sharps, et al., “Prion Neuropathology Follows the Accumulation of Alternate Prion Protein Isoforms After Infective Titre Has Peaked,” Nature Communications 5 (2014): 4347.

[497] C. Marrero-Winkens, C. Sankaran, and H. M. Schätzl, “From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins,” Biomolecules 10, no. 9 (2020): 1305.

[498] J. A. Richt, P. Kasinathan, A. N. Hamir, et al., “Production of Cattle Lacking Prion Protein,” Nature Biotechnology 25, no. 1 (2007): 132–138.

[499] A. Singh, S. Haldar, K. Horback, et al., “Prion Protein Regulates Iron Transport by Functioning as a Ferrireductase,” Journal of Alzheimer's Disease 35, no. 3 (2013): 541–552.

[500] B. S. Wong, S. G. Chen, M. Colucci, et al., “Aberrant Metal Binding by Prion Protein in Human Prion Disease,” Journal of Neurochemistry 78, no. 6 (2001): 1400–1408.

[501] A. H. Emwas, Z. A. Al-Talla, X. Guo, S. Al-Ghamdi, and H. T. Al-Masri, “Utilizing NMR and EPR Spectroscopy to Probe the Role of Copper in Prion Diseases,” Magnetic Resonance in Chemistry 51, no. 5 (2013): 255–268.

[502] L. Varela-Nallar, A. González, and N. C. Inestrosa, “Role of Copper in Prion Diseases: Deleterious or Beneficial?,” Current Pharmaceutical Design 12, no. 20 (2006): 2587–2595.

[503] E. Meneghetti, L. Gasperini, T. Virgilio, et al., “Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-Symptomatic and Terminal Stages of Prion Diseases,” Molecular Neurobiology 56, no. 9 (2019): 6035–6045.

[504] R. A. Alsiary, M. Alghrably, A. Saoudi, et al., “Using NMR Spectroscopy to Investigate the Role Played by Copper in Prion Diseases,” Neurological Sciences 41, no. 9 (2020): 2389–2406.

[505] E. M. Sigurdsson, D. R. Brown, M. A. Alim, et al., “Copper Chelation Delays the Onset of Prion Disease,” Journal of Biological Chemistry 278, no. 47 (2003): 46199–46202.

[506] A. C. Badrick and C. E. Jones, “The Amyloidogenic Region of the Human Prion Protein Contains a High Affinity (Met)(2)(His)(2) Cu(I) Binding Site,” Journal of Inorganic Biochemistry 103, no. 8 (2009): 1169–1175.

[507] G. Zhong, X. Wang, J. Li, et al., “Insights Into the Role of Copper in Neurodegenerative Diseases and the Therapeutic Potential of Natural Compounds,” Current Neuropharmacology 22, no. 10 (2024): 1650–1671.

[508] U. Rüb, J. P. Vonsattel, H. Heinsen, and H. W. Korf, “The Neuropathology of Huntington´s Disease: Classical Findings, Recent Developments and Correlation to Functional Neuroanatomy,” Advances in Anatomy, Embryology and Cell Biology 217 (2015): 1–146.

[509] E. M. van Well, V. Bader, M. Patra, et al., “A Protein Quality Control Pathway Regulated by Linear Ubiquitination,” EMBO Journal 38, no. 9 (2019): e100730.

[510] M. Politis, N. Lahiri, F. Niccolini, et al., “Increased Central Microglial Activation Associated With Peripheral Cytokine Levels in Premanifest Huntington's Disease Gene Carriers,” Neurobiology of Disease 83 (2015): 115–121.

[511] G. P. Bates, R. Dorsey, J. F. Gusella, et al., “Huntington Disease,” Nature Reviews Disease Primers 1 (2015): 15005.

[512] F. Saudou and S. Humbert, “The Biology of Huntingtin,” Neuron 89, no. 5 (2016): 910–926.

[513] E. B. Johnson, C. S. Parker, R. I. Scahill, et al., “Altered Iron and Myelin in Premanifest Huntington's Disease More Than 20 Years Before Clinical Onset: Evidence From the Cross-Sectional HD Young Adult Study,” EBioMedicine 65 (2021): 103266.

[514] M. Di Paola, O. R. Phillips, C. Sanchez-Castaneda, et al., “MRI Measures of Corpus Callosum Iron and Myelin in Early Huntington's Disease,” Human Brain Mapping 35, no. 7 (2014): 3143–3151.

[515] L. Niu, Y. Zhou, J. Wang, and W. Zeng, “Nuclear Translocation of STAT5 Initiates Iron Overload in huntington's Disease by Up-Regulating IRP1 Expression,” Metabolic Brain Disease 39, no. 4 (2024): 559–567.

[516] C. Sánchez-Castañeda, F. Squitieri, M. Di Paola, M. Dayan, M. Petrollini, and U. Sabatini, “The Role of Iron in Gray Matter Degeneration in Huntington's Disease: A Magnetic Resonance Imaging Study,” Human Brain Mapping 36, no. 1 (2015): 50–66.

[517] L. Chen, J. Hua, C. A. Ross, S. Cai, P. C. M. van Zijl, and X. Li, “Altered Brain Iron Content and Deposition Rate in Huntington's Disease as Indicated by Quantitative Susceptibility MRI,” Journal of Neuroscience Research 97, no. 4 (2019): 467–479.

[518] M. Bulk, I. Hegeman-Kleinn, B. Kenkhuis, et al., “Pathological Characterization of T2*-Weighted MRI Contrast in the Striatum of Huntington's Disease Patients,” NeuroImage Clinical 28 (2020): 102498.

[519] E. Bonilla, J. Estévez, H. Suárez, et al., “Serum Ferritin Deficiency in Huntington's Disease Patients,” Neuroscience Letters 129, no. 1 (1991): 22–24.

[520] L. Niu, C. Ye, Y. Sun, et al., “Mutant Huntingtin Induces Iron Overload via Up-Regulating IRP1 in Huntington's Disease,” Cell BioSciences 8 (2018): 41.

[521] J. Chen, E. Marks, B. Lai, et al., “Iron Accumulates in Huntington's Disease Neurons: Protection by Deferoxamine,” PLoS ONE 8, no. 10 (2013): e77023.

[522] K. L. Berggren, J. Chen, J. Fox, et al., “Neonatal Iron Supplementation Potentiates Oxidative Stress, Energetic Dysfunction and Neurodegeneration in the R6/2 Mouse Model of Huntington's Disease,” Redox Biology 4 (2015): 363–374.

[523] K. L. Berggren, Z. Lu, J. A. Fox, M. Dudenhoeffer, S. Agrawal, and J. H. Fox, “Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington's Disease Mice,” Journal of Huntington's Disease 5, no. 1 (2016): 53–63.

[524] D. A. Simmons, M. Casale, B. Alcon, N. Pham, N. Narayan, and G. Lynch, “Ferritin Accumulation in Dystrophic Microglia Is an Early Event in the Development of Huntington's Disease,” Glia 55, no. 10 (2007): 1074–1084.

[525] K. Berggren, S. Agrawal, J. A. Fox, et al., “Amyloid Precursor Protein Haploinsufficiency Preferentially Mediates Brain Iron Accumulation in Mice Transgenic for the Huntington's Disease Mutation,” Journal of Huntington's Disease 6, no. 2 (2017): 115–125.

[526] P. Dietrich, I. M. Johnson, S. Alli, and I. Dragatsis, “Elimination of Huntingtin in the Adult Mouse Leads to Progressive Behavioral Deficits, Bilateral Thalamic Calcification, and Altered Brain Iron Homeostasis,” PLoS Genetics 13, no. 7 (2017): e1006846.

[527] D. T. Dexter, A. Carayon, F. Javoy-Agid, et al., “Alterations in the Levels of Iron, Ferritin and Other Trace Metals in Parkinson's Disease and Other Neurodegenerative Diseases Affecting the Basal Ganglia,” Brain 114, no. pt 4 (1991): 1953–1975.

[528] G. Xiao, Q. Fan, X. Wang, and B. Zhou, “Huntington Disease Arises From a Combinatory Toxicity of Polyglutamine and Copper Binding,” PNAS 110, no. 37 (2013): 14995–15000.

[529] S. L. Hands, R. Mason, M. U. Sajjad, F. Giorgini, and A. Wyttenbach, “Metallothioneins and Copper Metabolism Are Candidate Therapeutic Targets in Huntington's Disease,” Biochemical Society Transactions 38, no. 2 (2010): 552–558.

[530] A. Zappu, O. Magli, M. B. Lepori, et al., “High Incidence and Allelic Homogeneity of Wilson Disease in 2 Isolated Populations: A Prerequisite for Efficient Disease Prevention Programs,” Journal of Pediatric Gastroenterology and Nutrition 47, no. 3 (2008): 334–338.

[531] C. Lo and O. Bandmann, “Epidemiology and Introduction to the Clinical Presentation of Wilson Disease,” Handbook of Clinical Neurology 142 (2017): 7–17.

[532] O. Bandmann, K. H. Weiss, and S. G. Kaler, “Wilson's Disease and Other Neurological Copper Disorders,” Lancet Neurology 14, no. 1 (2015): 103–113.

[533] A. J. Coffey, M. Durkie, S. Hague, et al., “A Genetic Study of Wilson's Disease in the United Kingdom,” Brain 136, no. pt 5 (2013): 1476–1487.

[534] R. Bruha, Z. Marecek, L. Pospisilova, et al., “Long-Term Follow-Up of Wilson Disease: Natural History, Treatment, Mutations Analysis and Phenotypic Correlation,” Liver International 31, no. 1 (2011): 83–91.

[535] K. Pak, S. Ordway, B. Sadowski, M. Canevari, and D. Torres, “Wilson's Disease and Iron Overload: Pathophysiology and Therapeutic Implications,” Clinical Liver Disease (Hoboken) 17, no. 2 (2021): 61–66.

[536] Y. Shiono, S. Wakusawa, H. Hayashi, et al., “Iron Accumulation in the Liver of Male Patients With Wilson's Disease,” American Journal of Gastroenterology 96, no. 11 (2001): 3147–3151.

[537] M. Kerkhof and P. Honkoop, “Never Forget Aceruloplasminemia in Case of Highly Suggestive Wilson's Disease Score,” Hepatology 59, no. 4 (2014): 1645–1647.

[538] A. Piperno and M. Alessio, “Aceruloplasminemia: Waiting for an Efficient Therapy,” Frontiers in Neuroscience 12 (2018): 903.

[539] L. Banci, I. Bertini, F. Cantini, A. C. Rosenzweig, and L. A. Yatsunyk, “Metal Binding Domains 3 and 4 of the Wilson Disease Protein: Solution Structure and Interaction With the Copper(I) Chaperone HAH1,” Biochemistry 47, no. 28 (2008): 7423–7429.

[540] B. Ruttkay-Nedecky, L. Nejdl, J. Gumulec, et al., “The Role of Metallothionein in Oxidative Stress,” International Journal of Molecular Sciences 14, no. 3 (2013): 6044–6066.

[541] H. Hayashi, M. Yano, Y. Fujita, and S. Wakusawa, “Compound Overload of Copper and Iron in Patients With Wilson's Disease,” Medical Molecular Morphology 39, no. 3 (2006): 121–126.

[542] Y. Li, J. Ma, R. Wang, Y. Luo, S. Zheng, and X. Wang, “Zinc Transporter 1 Functions in Copper Uptake and Cuproptosis,” Cell Metabolism 36, no. 9 (2024): 2118–2129.e2116.

[543] P. Rangarh and N. Kohli, “Neuroimaging Findings in Menkes Disease: A Rare Neurodegenerative Disorder,” BMJ Case Reports 2018 (2018): bcr2017223858.

[544] L. Poulsen, L. B. Møller, K. Plunkett, J. Belmont, Z. Tümer, and N. Horn, “X-Linked Menkes Disease: First Documented Report of Germ-Line Mosaicism,” Genetic Testing 8, no. 3 (2004): 286–291.

[545] Z. Tümer, L. B. Møller, and N. Horn, “Screening of 383 Unrelated Patients Affected With Menkes Disease and Finding of 57 Gross Deletions in ATP7A,” Human Mutation 22, no. 6 (2003): 457–464.

[546] B. Borm, L. B. Møller, I. Hausser, et al., “Variable Clinical Expression of an Identical Mutation in the ATP7A Gene for Menkes Disease/Occipital Horn Syndrome in Three Affected Males in a Single family,” Jornal de Pediatria 145, no. 1 (2004): 119–121.

[547] J. Tang, S. Robertson, K. E. Lem, S. C. Godwin, and S. G. Kaler, “Functional Copper Transport Explains Neurologic Sparing in Occipital Horn Syndrome,” Genetics in Medicine 8, no. 11 (2006): 711–718.

[548] M. Lenartowicz, R. R. Starzyński, W. Krzeptowski, et al., “Haemolysis and Perturbations in the Systemic Iron Metabolism of Suckling, Copper-Deficient Mosaic Mutant Mice—An Animal Model of Menkes Disease,” PLoS ONE 9, no. 9 (2014): e107641.

[549] H. Shim and Z. L. Harris, “Genetic Defects in Copper Metabolism,” Journal of Nutrition 133, no. 5 suppl 1 (2003): 1527s–1531s.

[550] S. Gulec and J. F. Collins, “Silencing the Menkes Copper-Transporting ATPase (Atp7a) Gene in Rat Intestinal Epithelial (IEC-6) Cells Increases Iron Flux via Transcriptional Induction of Ferroportin 1 (Fpn1),” Journal of Nutrition 144, no. 1 (2014): 12–19.

[551] Z. Tümer, “An Overview and Update of ATP7A Mutations Leading to Menkes Disease and Occipital Horn Syndrome,” Human Mutation 34, no. 3 (2013): 417–429.

[552] C. Moglia, A. Calvo, M. Brunetti, A. Chiò, and M. Grassano, “Broadening the Clinical Spectrum of FUS Mutations: A Case With Monomelic Amyotrophy With a Late Progression to Amyotrophic Lateral Sclerosis,” Neurological Sciences 42, no. 3 (2021): 1207–1209.

[553] L. Xu, T. Liu, L. Liu, et al., “Global Variation in Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis,” Journal of Neurology 267, no. 4 (2020): 944–953.

[554] K. C. Arthur, A. Calvo, T. R. Price, J. T. Geiger, A. Chiò, and B. J. Traynor, “Projected Increase in Amyotrophic Lateral Sclerosis From 2015 to 2040,” Nature Communications 7 (2016): 12408.

[555] L. P. Rowland and N. A. Shneider, “Amyotrophic Lateral Sclerosis,” New England Journal of Medicine 344, no. 22 (2001): 1688–1700.

[556] S. A. Goutman, O. Hardiman, A. Al-Chalabi, et al., “Emerging Insights Into the Complex Genetics and Pathophysiology of Amyotrophic Lateral Sclerosis,” Lancet Neurology 21, no. 5 (2022): 465–479.

[557] A. E. Renton, A. Chiò, and B. J. Traynor, “State of Play in Amyotrophic Lateral Sclerosis Genetics,” Nature Neuroscience 17, no. 1 (2014): 17–23.

[558] F. Akçimen, E. R. Lopez, J. E. Landers, et al., “Amyotrophic Lateral Sclerosis: Translating Genetic Discoveries Into Therapies,” Nature Reviews Genetics 24, no. 9 (2023): 642–658.

[559] N. Sanghai and G. K. Tranmer, “Hydrogen Peroxide and Amyotrophic Lateral Sclerosis: From Biochemistry to Pathophysiology,” Antioxidants (Basel) 11, no. 1 (2021): 52.

[560] A. Russo, S. Putaggio, E. Tellone, et al., “Emerging Ferroptosis Involvement in Amyotrophic Lateral Sclerosis Pathogenesis: Neuroprotective Activity of Polyphenols,” Molecules 30, no. 6 (2025): 1211.

[561] Y. Mizuno, M. Amari, M. Takatama, H. Aizawa, B. Mihara, and K. Okamoto, “Transferrin Localizes in Bunina Bodies in Amyotrophic Lateral Sclerosis,” Acta Neuropathologica 112, no. 5 (2006): 597–603.

[562] E. A. Winkler, J. D. Sengillo, A. P. Sagare, et al., “Blood-Spinal Cord Barrier Disruption Contributes to Early Motor-Neuron Degeneration in ALS-Model Mice,” PNAS 111, no. 11 (2014): E1035–E1042.

[563] M. Hadzhieva, E. Kirches, A. Wilisch-Neumann, et al., “Dysregulation of Iron Protein Expression in the G93A Model of Amyotrophic Lateral Sclerosis,” Neuroscience 230 (2013): 94–101.

[564] S. Y. Jeong, K. I. Rathore, K. Schulz, P. Ponka, P. Arosio, and S. David, “Dysregulation of Iron Homeostasis in the CNS Contributes to Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis,” Journal of Neuroscience 29, no. 3 (2009): 610–619.

[565] M. Halon-Golabek, A. Borkowska, J. J. Kaczor, et al., “hmSOD1 Gene Mutation-Induced Disturbance in Iron Metabolism Is Mediated by Impairment of Akt Signalling Pathway,” Journal of Cachexia, Sarcopenia and Muscle 9, no. 3 (2018): 557–569.

[566] A. Popović-Bijelić, M. Mojović, S. Stamenković, et al., “Iron-Sulfur Cluster Damage by the Superoxide Radical in Neural Tissues of the SOD1(G93A) ALS Rat Model,” Free Radical Biology and Medicine 96 (2016): 313–322.

[567] L. F. Tu, T. Z. Zhang, Y. F. Zhou, et al., “GPX4 Deficiency-Dependent Phospholipid Peroxidation Drives Motor Deficits of ALS,” Journal of Advanced Research 43 (2023): 205–218.

[568] Y. Furukawa, K. Kaneko, K. Yamanaka, T. V. O'Halloran, and N. Nukina, “Complete Loss of Post-Translational Modifications Triggers Fibrillar Aggregation of SOD1 in the Familial Form of Amyotrophic Lateral Sclerosis,” Journal of Biological Chemistry 283, no. 35 (2008): 24167–24176.

[569] F. A. Sala, G. S. A. Wright, S. V. Antonyuk, R. C. Garratt, and S. S. Hasnain, “Molecular Recognition and Maturation of SOD1 by Its Evolutionarily Destabilised Cognate Chaperone hCCS,” PLoS Biology 17, no. 2 (2019): e3000141.

[570] R. Rakhit, J. Robertson, C. Vande Velde, et al., “An Immunological Epitope Selective for Pathological Monomer-Misfolded SOD1 in ALS,” Nature Medicine 13, no. 6 (2007): 754–759.

[571] G. S. A. Wright, “Molecular and Pharmacological Chaperones for SOD1,” Biochemical Society Transactions 48, no. 4 (2020): 1795–1806.

[572] M. T. Wallin, W. J. Culpepper, J. D. Campbell, et al., “The Prevalence of MS in the United States: A Population-Based Estimate Using Health Claims Data,” Neurology 92, no. 10 (2019): e1029–e1040.

[573] C. F. Lucchinetti, B. F. Popescu, R. F. Bunyan, et al., “Inflammatory Cortical Demyelination in Early Multiple Sclerosis,” New England Journal of Medicine 365, no. 23 (2011): 2188–2197.

[574] J. M. Frischer, S. Bramow, A. Dal-Bianco, et al., “The Relation Between Inflammation and Neurodegeneration in Multiple Sclerosis Brains,” Brain 132, no. pt 5 (2009): 1175–1189.

[575] M. P. McGinley, C. H. Goldschmidt, and A. D. Rae-Grant, “Diagnosis and Treatment of Multiple Sclerosis: A Review,” JAMA 325, no. 8 (2021): 765–779.

[576] N. A. Patsopoulos, L. F. Barcellos, R. Q. Hintzen, et al., “Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects,” PLoS Genetics 9, no. 11 (2013): e1003926.

[577] A. M. Elkady, D. Cobzas, H. Sun, G. Blevins, and A. H. Wilman, “Progressive Iron Accumulation Across Multiple Sclerosis Phenotypes Revealed by Sparse Classification of Deep Gray Matter,” Journal of Magnetic Resonance Imaging 46, no. 5 (2017): 1464–1473.

[578] L. Haider, T. Zrzavy, S. Hametner, et al., “The Topograpy of Demyelination and Neurodegeneration in the Multiple Sclerosis Brain,” Brain 139, no. pt 3 (2016): 807–815.

[579] M. Absinta, P. Sati, F. Masuzzo, et al., “Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo,” JAMA Neurology 76, no. 12 (2019): 1474–1483.

[580] H. Hu, L. Ye, S. Ding, et al., “The Heterogeneity of Tissue Destruction Between Iron Rim Lesions and Non-Iron Rim Lesions in Multiple Sclerosis: A Diffusion MRI Study,” Multiple Sclerosis and Related Disorders 66 (2022): 104070.

[581] W. Chen, S. A. Gauthier, A. Gupta, et al., “Quantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages,” Radiology 271, no. 1 (2014): 183–192.

[582] L. Haider, “Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis,” Oxidative Medicine and Cellular Longevity 2015 (2015): 725370.

[583] S. Hametner, I. Wimmer, L. Haider, S. Pfeifenbring, W. Brück, and H. Lassmann, “Iron and Neurodegeneration in the Multiple Sclerosis Brain,” Annals of Neurology 74, no. 6 (2013): 848–861.

[584] C. L. Hu, M. Nydes, K. L. Shanley, I. E. Morales Pantoja, T. A. Howard, and O. A. Bizzozero, “Reduced Expression of the Ferroptosis Inhibitor Glutathione Peroxidase-4 in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis,” Journal of Neurochemistry 148, no. 3 (2019): 426–439.

[585] J. Y. Luoqian, W. Yang, X. Ding, et al., “Ferroptosis Promotes T-Cell Activation-Induced Neurodegeneration in Multiple Sclerosis,” Cellular & Molecular Immunology 19, no. 8 (2022): 913–924.

[586] A. Rayatpour, F. Foolad, M. Heibatollahi, K. Khajeh, and M. Javan, “Ferroptosis Inhibition by Deferiprone, Attenuates Myelin Damage and Promotes Neuroprotection in Demyelinated Optic Nerve,” Scientific Reports 12, no. 1 (2022): 19630.

[587] R. Shu, L. Zhang, H. Zhang, et al., “NMDA Receptor Modulates Spinal Iron Accumulation via Activating DMT1(-)IRE in Remifentanil-Induced Hyperalgesia,” Journal of Pain 22, no. 1 (2021): 32–47.

[588] D. Mahad, I. Ziabreva, H. Lassmann, and D. Turnbull, “Mitochondrial Defects in Acute Multiple Sclerosis Lesions,” Brain 131, no. pt 7 (2008): 1722–1735.

[589] Y. J. Lee, X. Huang, J. Kropat, et al., “Sphingolipid Signaling Mediates Iron Toxicity,” Cell Metabolism 16, no. 1 (2012): 90–96.

[590] K. Joppe, A. E. Roser, F. Maass, and P. Lingor, “The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System,” Frontiers in Neuroscience 13 (2019): 15.

[591] S. Faissner, M. Mishra, D. K. Kaushik, et al., “Systematic Screening of Generic Drugs for Progressive Multiple Sclerosis Identifies Clomipramine as a Promising Therapeutic,” Nature Communications 8, no. 1 (2017): 1990.

[592] J. van Horssen, M. E. Witte, G. Schreibelt, and H. E. de Vries, “Radical Changes in Multiple Sclerosis Pathogenesis,” Biochimica et Biophysica Acta 1812, no. 2 (2011): 141–150.

[593] S. Sheykhansari, K. Kozielski, J. Bill, et al., “Redox Metals Homeostasis in Multiple Sclerosis and Amyotrophic Lateral Sclerosis: A Review,” Cell Death & Disease 9, no. 3 (2018): 348.

[594] S. Wergeland, Ø. Torkildsen, K. M. Myhr, S. J. Mørk, and L. Bø, “The Cuprizone Model: Regional Heterogeneity of Pathology,” APMIS 120, no. 8 (2012): 648–657.

[595] P. N. Koutsoudaki, T. Skripuletz, V. Gudi, et al., “Demyelination of the Hippocampus Is Prominent in the Cuprizone Model,” Neuroscience Letters 451, no. 1 (2009): 83–88.

[596] R. J. Ward, F. A. Zucca, J. H. Duyn, R. R. Crichton, and L. Zecca, “The Role of Iron in Brain Ageing and Neurodegenerative Disorders,” Lancet Neurology 13, no. 10 (2014): 1045–1060.

[597] L. C. Beauchamp, X. M. Liu, L. J. Vella, et al., “ATH434 Rescues Pre-Motor Hyposmia in a Mouse Model of Parkinsonism,” Neurotherapeutics 19, no. 6 (2022): 1966–1975.

[598] M. T. Nuñez and P. Chana-Cuevas, “New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases,” Pharmaceuticals (Basel) 11, no. 4 (2018): 109.

[599] V. Prachayasittikul, S. Prachayasittikul, S. Ruchirawat, and V. Prachayasittikul, “8-Hydroxyquinolines: A Review of Their Metal Chelating Properties and Medicinal Applications,” Drug Design, Development and Therapy 7 (2013): 1157–1178.

[600] R. J. Ward, D. T. Dexter, and R. R. Crichton, “Neurodegenerative Diseases and Therapeutic Strategies Using Iron Chelators,” Journal of Trace Elements in Medicine and Biology 31 (2015): 267–273.

[601] P. J. Crouch, L. W. Hung, P. A. Adlard, et al., “Increasing Cu Bioavailability Inhibits Abeta Oligomers and Tau Phosphorylation,” PNAS 106, no. 2 (2009): 381–386.

[602] L. J. Ellett, L. W. Hung, R. Munckton, et al., “Restoration of Intestinal Function in an MPTP Model of Parkinson's Disease,” Scientific Reports 6 (2016): 30269.

[603] C. P. W. Soon, P. S. Donnelly, B. J. Turner, et al., “Diacetylbis(N(4)-Methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects Against Peroxynitrite-Induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model,” Journal of Biological Chemistry 286, no. 51 (2011): 44035–44044.

[604] J. R. Williams, E. Trias, P. R. Beilby, et al., “Copper Delivery to the CNS by CuATSM Effectively Treats Motor Neuron Disease in SOD(G93A) Mice Co-Expressing the Copper-Chaperone-for-SOD,” Neurobiology of Disease 89 (2016): 1–9.

[605] J. B. W. Hilton, K. Kysenius, J. R. Liddell, et al., “Evidence for Disrupted Copper Availability in human Spinal Cord Supports Cu(II)(atsm) as a Treatment Option for Sporadic Cases of ALS,” Scientific Reports 14 (2024): 5929.

[606] I. Mohr, B. Hélène, W. France, et al., “Experience on Switching Trientine Formulations in Wilson Disease: Efficacy and Safety After Initiation of TETA 4HCl as Substitute for TETA 2HCl.” Journal of Gastroenterology and Hepatology 38, no. 2 (2022): 219–224.

[607] H. Kodama, E. Sato, Y. H. Gu, K. Shiga, C. Fujisawa, and T. Kozuma, “Effect of Copper and Diethyldithiocarbamate Combination Therapy on the Macular Mouse, an Animal Model of Menkes Disease,” Journal of Inherited Metabolic Disease 28, no. 6 (2005): 971–978.

[608] P. A. Adlard, R. A. Cherny, D. I. Finkelstein, et al., “Rapid Restoration of Cognition in Alzheimer's Transgenic Mice With 8-Hydroxy Quinoline Analogs Is Associated With Decreased Interstitial Abeta,” Neuron 59, no. 1 (2008): 43–55.

[609] S. H. Liang, A. G. Southon, B. H. Fraser, et al., “Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease,” ACS Medicinal Chemistry Letters 6, no. 9 (2015): 1025–1029.

[610] K. D. Fasae, A. O. Abolaji, T. R. Faloye, et al., “Metallobiology and Therapeutic Chelation of Biometals (Copper, Zinc and Iron) in Alzheimer's Disease: Limitations, and Current and Future Perspectives,” Journal of Trace Elements in Medicine and Biology 67 (2021): 126779.

[611] V. Oliveri and G. Vecchio, “8-Hydroxyquinolines in Medicinal Chemistry: A Structural Perspective,” European Journal of Medicinal Chemistry 120 (2016): 252–274.

[612] M. Albrecht, M. Fiege, and O. Osetska, “8-Hydroxyquinolines in Metallosupramolecular Chemistry,” Coordination Chemistry Reviews 252, no. 8 (2008): 812–824.

[613] H. Jiang, J. E. Taggart, X. Zhang, D. M. Benbrook, S. E. Lind, and W. Q. Ding, “Nitroxoline (8-Hydroxy-5-Nitroquinoline) Is More a Potent Anti-Cancer Agent Than Clioquinol (5-Chloro-7-Iodo-8-Quinoline),” Cancer Letters 312, no. 1 (2011): 11–17.

[614] S. Tardito, A. Barilli, I. Bassanetti, et al., “Copper-Dependent Cytotoxicity of 8-Hydroxyquinoline Derivatives Correlates With Their Hydrophobicity and Does Not Require Caspase Activation,” Journal of Medicinal Chemistry 55, no. 23 (2012): 10448–10459.

[615] G. J. Brewer, F. Askari, R. B. Dick, et al., “Treatment of Wilson's Disease With Tetrathiomolybdate: V. Control of Free Copper by Tetrathiomolybdate and a Comparison With Trientine,” Translational Research 154, no. 2 (2009): 70–77.

[616] W. Stremmel, “Bis-Choline Tetrathiomolybdate as Old Drug in a New Design for Wilson's Disease: Good for Brain and Liver?,” Hepatology 69, no. 2 (2019): 901–903.

[617] D. E. Ehrnhoefer, J. Bieschke, A. Boeddrich, et al., “EGCG Redirects Amyloidogenic Polypeptides Into Unstructured, Off-Pathway Oligomers,” Nature Structural & Molecular Biology 15, no. 6 (2008): 558–566.

[618] A. Sadžak, I. Vlašić, Z. Kiralj, et al., “Neurotoxic Effect of Flavonol Myricetin in the Presence of Excess Copper,” Molecules 26, no. 4 (2021): 845.

[619] N. A. Singh, A. K. Mandal, and Z. A. Khan, “Potential Neuroprotective Properties of Epigallocatechin-3-Gallate (EGCG),” Nutrition Journal 15, no. 1 (2016): 60.

[620] J. Patwa and S. J. S. Flora, “Copper: From Enigma to Therapeutic Target for Neurological Disorder,” Basic & Clinical Pharmacology & Toxicology 134, no. 6 (2024): 778–791.

[621] R. J. Ward, D. T. Dexter, and R. R. Crichton, “Chelating Agents for Neurodegenerative Diseases,” Current Medicinal Chemistry 19, no. 17 (2012): 2760–2772.

[622] C. L. Fu, L. S. Hsu, Y. F. Liao, and M. K. Hu, “New Hydroxyquinoline-Based Derivatives as Potent Modulators of Amyloid-β Aggregations,” Archiv der Pharmazie (Weinheim) 349, no. 5 (2016): 327–341.

[623] V. Oliveri, “New Glycoconjugates for the Treatment of Diseases Related to Metal Dyshomeostasis,” ChemistryOpen 4, no. 6 (2015): 792–795.

[624] V. Oliveri, G. I. Grasso, F. Bellia, F. Attanasio, M. Viale, and G. Vecchio, “Soluble Sugar-Based Quinoline Derivatives as New Antioxidant Modulators of Metal-Induced Amyloid Aggregation,” Inorganic Chemistry 54, no. 6 (2015): 2591–2602.

[625] A. H. Abdeen, B. G. Trist, and K. L. Double, “Empirical Evidence for Biometal Dysregulation in Parkinson's Disease From a Systematic Review and Bradford Hill Analysis,” NPJ Parkinson's Disease 8, no. 1 (2022): 83.

[626] N. Tiyoula, F. V. Sharbaf, K. Rahimian, et al., “Artificial Intelligence in Metalloprotein Binding Site Prediction: A Systematic Review Bridging Bioinformatics and Biotechnology,” International Journal of Biological Macromolecules 323, no. pt 2 (2025): 146666.

[627] H. Nguyen and J. Kleingardner, “Identifying Metal Binding Amino Acids Based on Backbone Geometries as a Tool for Metalloprotein Engineering,” Protein Science 30, no. 6 (2021): 1247–1257.

[628] M. Brylinski and J. Skolnick, “FINDSITE-Metal: Integrating Evolutionary Information and Machine Learning for Structure-Based Metal-Binding Site Prediction at the Proteome Level,” Proteins 79, no. 3 (2011): 735–751.

[629] M. Oostrom, S. Akers, N. Garrett, E. Hanson, W. Shaw, and J. A. Laureanti, “Classifying Metal-Binding Sites With Neural Networks,” Protein Science 32, no. 3 (2023): e4591.

[630] A. Mohamadi, T. F. Cheng, L. J. Jin, J. W. Wang, H. Z. Sun, and M. Koohi-Moghadam, “An Ensemble 3D Deep-Learning Model to Predict Protein Metal-Binding Site,” Cell Reports Physical Science 3, no. 9 (2022): 101046.

[631] J. L. Yu, Y. G. Wang, J. Peng, J. W. Wu, C. Zhou, and G. B. Li, “Geometric Deep Learning-Enabled Metal-Binding Site Identification and Grafting,” Fundamental Research (2024), in press.

[632] A. A. Aptekmann, J. Buongiorno, D. Giovannelli, M. Glamoclija, D. U. Ferreiro, and Y. Bromberg, “mebipred: Identifying Metal-Binding Potential in Protein Sequence,” Bioinformatics 38, no. 14 (2022): 3532–3540.

[633] R. Fernández-Díaz, L. Roldán-Martín, M. Sodupe, J. E. Sánchez-Aparicio, and J. D. Maréchal, “BioBrigit, a Hybrid Machine Learning and Knowledge-Based Approach to Model Metal Pathways in Proteins: Application to a Dicopper Tyrosinase,” ACS Omega 10, no. 23 (2025): 24412–24421.

[634] D. Chaparro, A. Flores-Gaspar, and J. Alí-Torres, “Computational Design of Copper Ligands With Controlled Metal Chelating, Pharmacokinetics, and Redox Properties for Alzheimer's Disease,” Journal of Alzheimer's Disease 82, no. s1 (2021): S179–S193.

[635] L. Holzhauer, V. Shekhovtsev, C. Bruschi, et al., “Identification of Novel Triazolylquinoxaline-Based Metal Complexes Supported by Experimental and Virtual Screenings,” Dalton Transactions 54, no. 8 (2025): 3287–3295.

[636] S. Michael, P. Jeyaraman, B. Marimuthu, et al., “Pharmaceutical Manifestation of Knoevenagel Condensed Metal (II) Complexes Through Virtual, In Vitro and In Vivo Assessments,” Journal of Biomolecular Structure & Dynamics 43, no. 8 (2025): 4028–4042.

[637] R. Squitti, M. Siotto, M. Arciello, and L. Rossi, “Non-Ceruloplasmin Bound Copper and ATP7B Gene Variants in Alzheimer's Disease,” Metallomics 8, no. 9 (2016): 863–873.

[638] X. Zhou, W. Zhou, C. Wang, et al., “A Comprehensive Analysis and Splicing Characterization of Naturally Occurring Synonymous Variants in the ATP7B Gene,” Frontiers in Genetics 11 (2020): 592611.

[639] Y. Hatano, T. Ishihara, and O. Onodera, “Accuracy of a Machine Learning Method Based on Structural and Locational Information From AlphaFold2 for Predicting the Pathogenicity of TARDBP and FUS Gene Variants in ALS,” BMC Bioinformatics [Electronic Resource] 24, no. 1 (2023): 206.

[640] C. T. Hsiao, T. F. Tropea, S. J. Fu, et al., “Rare Gain-of-Function KCND3 Variant Associated With Cerebellar Ataxia, Parkinsonism, Cognitive Dysfunction, and Brain Iron Accumulation,” International Journal of Molecular Sciences 22, no. 15 (2021): 8247.

[641] D. McLean, M. J. Cooke, Y. Wang, et al., “Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains,” PLoS ONE 7, no. 12 (2012): e51958.

[642] L. D. Adair, B. G. Trist, M. E. Graziotto, et al., “Imaging Copper Levels During Life in the Brain and Beyond Using a Fluorescent Copper Sensor With Multimodal Capacity,” Chemical & Biomedical Imaging 3, no. 10 (2025): 653–662.

[643] M. Ikawa, H. Okazawa, Y. Nakamoto, and M. Yoneda, “PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated With Mitochondrial Dysfunction,” Antioxidants (Basel) 9, no. 9 (2020): 861.

[644] H. Neishi, M. Ikawa, H. Okazawa, et al., “Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients With Parkinson's Disease: A Study With 62Cu-ATSM PET and 123I-FP-CIT SPECT,” European Neurology 78, no. 3–4 (2017): 161–168.

[645] M. Ikawa, H. Okazawa, T. Tsujikawa, et al., “Increased Oxidative Stress Is Related to Disease Severity in the ALS Motor Cortex: A PET Study,” Neurology 84, no. 20 (2015): 2033–2039.

[646] H. Okazawa, M. Ikawa, T. Tsujikawa, et al., “Cerebral Oxidative Stress in Early Alzheimer's Disease Evaluated by (64)Cu-ATSM PET/MRI: A Preliminary Study,” Antioxidants (Basel) 11, no. 5 (2022): 1022.

[647] C. Lopes, I. L. Ferreira, C. Maranga, et al., “Mitochondrial and Redox Modifications in Early Stages of Huntington's Disease,” Redox Biology 56 (2022): 102424.

[648] M. T. Fodero-Tavoletti, V. L. Villemagne, B. M. Paterson, et al., “Bis(thiosemicarbazonato) Cu-64 Complexes for Positron Emission Tomography Imaging of Alzheimer's Disease,” Journal of Alzheimer's Disease 20, no. 1 (2010): 49–55.

[649] J. B. Torres, E. M. Andreozzi, J. T. Dunn, et al., “PET Imaging of Copper Trafficking in a Mouse Model of Alzheimer Disease,” Journal of Nuclear Medicine 57, no. 1 (2016): 109–114.

[650] H. J. Cho, T. T. Huynh, B. E. Rogers, and L. M. Mirica, “Design of a Multivalent Bifunctional Chelator for Diagnostic (64)Cu PET Imaging in Alzheimer's Disease,” PNAS 117, no. 49 (2020): 30928–30933.

[651] B. Nam, W. Lee, S. Sarkar, et al., “In Vivo Detection of Hydrogen Sulfide in the Brain of Live Mouse: Application in Neuroinflammation Models,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 12 (2022): 4073–4087.

[652] M. Shojaei, R. Schaefer, K. Schlepckow, et al., “PET Imaging of Microglia in Alzheimer's Disease Using Copper-64 Labeled TREM2 Antibodies,” Theranostics 14, no. 16 (2024): 6319–6336.

[653] Z. Adeli, S. A. Hosseini, Y. Salimi, N. Vahidfar, and P. Sheikhzadeh, “A CT-Free Deep-Learning-Based Attenuation and Scatter Correction for Copper-64 PET in Different Time-Point Scans,” Radiological Physics and Technology 18, no. 2 (2025): 523–533.

[654] Y. Y. Zhang, X. S. Li, K. D. Ren, J. Peng, and X. J. Luo, “Restoration of Metal Homeostasis: A Potential Strategy Against Neurodegenerative Diseases,” Ageing Research Reviews 87 (2023): 101931.

[655] V. N. Pham and C. J. Chang, “Metalloallostery and Transition Metal Signaling: Bioinorganic Copper Chemistry Beyond Active Sites,” Angewandte Chemie 62, no. 11 (2023): e202213644.

[656] J. L. Liu, Y. G. Fan, Z. S. Yang, Z. Y. Wang, and C. Guo, “Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications,” Frontiers in Neuroscience 12 (2018): 632.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.